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Abstract 
Many respiratory tract infections are treated with macrolide antibiotics. Regulatory agencies 
warn that these antibiotics increase the risk of ventricular arrhythmia. This population-based 
retrospective cohort study examined the 30-day risk of a hospital encounter with ventricular 
arrhythmia and all-cause mortality in 503,612 matched pairs of older adults who received a 
new outpatient prescription for an oral macrolide antibiotic and those prescribed referent 
antibiotics from 2002 to 2013 in Ontario. Conditional logistic regression was used to measure 
the association between macrolide exposure and outcomes. Macrolide antibiotics compared 
with referent antibiotics were not associated with a higher 30-day risk of ventricular 
arrhythmia (0.03% vs. 0.03%, relative risk [RR] 1.06, 95% confidence interval [CI] 0.83-
1.36), and were associated with a lower risk of 30-day all-cause mortality (0.62% vs. 0.76%, 
RR 0.82, 95% CI 0.78-0.86). These findings suggest that current warnings from Health 
Canada and the U.S. Food and Drug Administration may be overstated.  
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Chapter 1  
1 Introduction 
Macrolide antibiotics (e.g. azithromycin, clarithromycin and erythromycin) are a 
common class of medications used to treat community-acquired respiratory tract 
infections (1–4). In 2010, over 57 million outpatient prescriptions were written for 
macrolide antibiotics in the United States (U.S.) (5). A recent observational study 
prompted Health Canada and the U.S. Food and Drug Administration (FDA) to issue 
warnings about the risk of QT interval prolongation and fatal ventricular arrhythmia with 
azithromycin use (6,7). This study showed a higher risk of cardiovascular death and  
all-cause mortality in patients prescribed azithromycin as compared with other antibiotic 
prescriptions (amoxicillin) or antibiotic non-use (8). Findings from this study were 
supported by prior case reports and published studies (9–15).  
Other recent studies suggest these regulatory warnings may be overstated (16–19). 
Mortensen et al. showed the risk of 90-day mortality was no higher (and rather was 
lower) in older patients who received azithromycin compared with other guideline-
concordant antibiotics (16). In the same study, there was no difference between the two 
groups in the risk of arrhythmia, heart failure or any cardiac event. Another study showed 
no higher 5-day risk of cardiovascular death with azithromycin compared with 
penicillin V (17). In a study of patients with radiologically confirmed community-
acquired pneumonia, clarithromycin compared with antibiotic non-use was associated 
with a higher risk of cardiovascular events, but not cardiovascular mortality or all-cause 
mortality (18). 
Given these conflicting findings, we conducted this large propensity-matched population-
based cohort study of older adults in the outpatient setting to investigate whether 
azithromycin, clarithromycin or erythromycin compared with non-macrolide referent 
antibiotics (amoxicillin, cefuroxime or levofloxacin) is associated with higher 30-day 
risks of ventricular arrhythmia and all-cause mortality.  
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Chapter 2  
2 Literature Review 
 
2.1 Outpatient macrolide antibiotic prescribing  
Community-acquired respiratory tract infections are common and potentially serious, 
especially in older adult patients and those with significant comorbidities (3). Macrolide 
antibiotics, such as azithromycin, clarithromycin and erythromycin, are often used in the 
treatment of such infections (4).  
In Canada and the U.S., influenza and pneumonia were the eighth leading cause of death 
in 2011 (20,21). In 2013, over $20 million was spent on outpatient macrolide 
prescriptions in Canada (2). In 2010, over 57 million outpatient prescriptions were 
written for macrolide antibiotics in the United States (5). 
 
2.2 Mechanism of macrolide antibiotic action 
Azithromycin and clarithromycin are derivatives of the older macrolide, erythromycin, 
although the mechanism of action of all three macrolides is similar. They bind reversibly 
to the 50S subunit of bacterial ribosomes, leading to inhibition of transpeptidation, 
translocation, chain elongation and bacterial protein synthesis (22,23). Macrolides are 
actively concentrated within leukocytes and are transported directly into the site of 
infection (24). Azithromycin and clarithromycin are more acid stable than erythromycin, 
providing improved oral absorption, tolerance, pharmacokinetic properties and a broader 
spectrum of antibacterial activity than erythromycin (22,23). 
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2.3 Mechanism of macrolide-induced QT interval 
prolongation 
The repolarization phase of cardiac muscle cells (myocytes) is driven predominantly by 
outward movement of potassium ions (K+). The rapid delayed rectifier current (IKr) is an 
important K+ current participating in ventricular repolarization (25). Blockade of this 
outward potassium current can prolong the cardiac action potential (25,26). Macrolide 
antibiotics are known to interfere with the IKr current, which results in accumulation of 
K+ in cardiac myocytes thereby delaying cardiac repolarization (26–28). This disturbance 
of myocardial repolarization is characterized by a prolonged QT interval on the 
electrocardiogram (ECG) known as long QT syndrome (LQTS) (29,30). LQTS is 
associated with an increased risk of cardiac arrhythmia referred to as torsades de pointes 
(31,32). The primary symptoms in patients with LQTS include palpitations, syncope, 
seizures and sudden cardiac death. This disorder may be either genetic or acquired 
(33,34). 
Erythromycin was the first macrolide to be associated with QT interval prolongation, but 
subsequent reports and studies have also described QT interval prolongation with 
azithromycin and clarithromycin use (14,15,35).  
 
2.4 Search strategy and quality assessment of prior studies 
 
We searched both MEDLINE (inception to June 2015) and Google Scholar (inception to 
June 2015) for relevant articles to include in our literature review. The purpose of our 
literature search was to identify prior studies that examined the association between 
macrolide antibiotic use and the outcomes of ventricular arrhythmia and mortality. For 
both databases, the final search strategy consisted of keywords such as macrolide, 
antibiotic, arrhythmia, mortality, respiratory tract infection, pneumonia, azithromycin, 
clarithromycin and erythromycin. We also used the related articles option in Google 
Scholar to search for additional articles and searched relevant review articles and 
reference lists of included articles.  
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Inclusion and exclusion criteria were developed a priori. Studies were included if they 
met the following criteria: (1) full-text English article, (2) randomized controlled trial 
(RCT) or cohort study, (3) more than 1,000 patients, (4) mean age 18 years or more and 
(5) reported ventricular arrhythmia (including composite outcomes) or mortality (all-
cause or cardiovascular). We excluded the following studies from our review: (1) no 
incidence of main outcomes (ventricular arrhythmia or mortality) reported and (2) 
insufficient information on the antibiotic exposure. Ten studies were identified as 
meeting our inclusion criteria. For purposes of our literature review, the term ‘antibiotic 
non-use’ refers to no antibiotic use of any kind. 
We evaluated the quality of individual studies using the Downs and Black quality 
assessment method, which is a list of 27 criteria to evaluate both randomized and non-
randomized trials (Appendix A) (36). This scale assesses the completeness and clarity of 
study reporting, external validity, internal validity (e.g. bias and confounding) and power. 
The tool was modified slightly for use in our review. Specifically, the scoring for 
question 27 dealing with statistical power was simplified to a choice of awarding either 1 
or 0 points depending on whether there was sufficient power to detect a clinically 
important effect. On the modified scale, we gave all included studies a score from 0 to 
28, grouped into the following four quality levels: excellent (26 to 28), good (20 to 25), 
fair (15 to 19) and poor (14 or less). 
Two reviewers (M.T. and R.J.) independently assessed the quality of the included 
articles. Discrepancies between the two reviewers were resolved through re-evaluation 
and discussion. We did not perform a meta-analysis because the studies were too 
heterogeneous. 
 
2.5 Summary of previous literature 
The findings of ten published studies (summarized in Table 1) describing the risk of 
ventricular arrhythmia or death with macrolide antibiotic use compared with other classes 
of antibiotics or antibiotic non-use are inconsistent. These studies vary in patient age, sex 
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and comorbidity. Our assessment of study quality using the Downs and Black quality 
checklist determined that six of the reviewed studies were of fair quality (8–10,16,18,37) 
and four were of good quality (11,12,17,19). 
 
2.6 Macrolide antibiotics and risk of ventricular arrhythmia 
One study included in our literature review reported an increased risk of 7-day ventricular 
arrhythmia with azithromycin use compared to amoxicillin-clavulanate treatment (odds 
ratio [OR] 4.32, 95% confidence interval [CI] 2.95-6.33) though the authors found no 
such risk with clarithromycin (OR 0.72, 95% CI 0.48-1.08) (12).  
Despite multiple case reports demonstrating evidence of QT prolongation with macrolide 
antibiotic use (13–15), two studies included in our literature review reported no 
significant increase in the risk of ventricular arrhythmia associated with macrolide use 
relative to other antibiotics (9,16). Rao et al. found no statistically different risk of 
arrhythmia with azithromycin compared with amoxicillin within 6 to 10 days (hazard 
ratio [HR] 1.37, 95% CI 0.91-2.05), though an increased risk was observed within 5 days 
of follow-up (HR 1.77, 95% CI 1.20-2.62) (9). Similarly, Mortensen et al. found no 
significantly different 90-day risk of cardiac arrhythmia when comparing azithromycin 
with other antibiotic use (OR 0.99, 95% CI 0.95-1.02) (16). The seven remaining studies 
did not examine arrhythmia risk (8,10,11,17–19,37). 
 
2.7 Macrolide antibiotics and risk of all-cause mortality 
Two studies included in our literature review reported a higher risk of all-cause mortality 
with macrolide antibiotic use (8,11) while four other studies reported no risk or a 
decreased risk of death from any cause (9,16,18,19). In an RCT of five Copenhagen 
cardiology departments, clarithromycin use relative to antibiotic non-use was associated 
with an increased risk of all-cause mortality during three years of follow-up (HR 1.27, 
95% CI 1.03-1.54) (11). Ray et al. found an increased 5-day risk of death from any cause 
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when comparing azithromycin with antibiotic non-use (HR 1.85, 95% CI 1.25-2.75) and 
amoxicillin (HR 2.02, 95% CI 1.24-3.30) (8). 
A population-based prospective cohort study of 2,779 outpatients with community-
acquired pneumonia assessed at seven Emergency Departments in Edmonton, Alberta 
found significantly lower 30-day mortality in patients receiving macrolides compared to 
another antibiotic (fluoroquinolone) (OR 0.28, 95% CI 0.09-0.86) (19). Three 
observational studies showed no risk or a decreased risk of all-cause mortality when 
comparing macrolides to other classes of antibiotics or antibiotic non-use at 6 to10 days 
(HR 1.14, 95% CI 0.81-1.62) (9), 30 days (OR 0.76, 95% CI 0.73-0.80) (16), 90 days 
(OR 0.73, 95% CI 0.70-0.76) (16) and one year of follow-up (HR 1.13, 95% CI 0.85-
1.51) (18). 
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Table 1. Literature summary of ten published studies describing cardiovascular events and mortality associated with macrolide use 
compared with other classes of antibiotics or antibiotic non-use for the treatment of respiratory tract infections 
 
Author Study Type /  Patient Description Observations 
Potential Risk 
Factors 
Dose / Exposure Time /  
Study Limitations 
Quality 
Scorea 
Randomized Controlled Trials 
Jespersen 
et al., 
2006 (11) 
-Five Copenhagen 
University cardiology 
departments and a 
coordinating centre 
-2,172 participants who had 
a discharge diagnosis of MI 
or angina pectoris from 1993 
to 1999 randomized to 
clarithromycin (mean age 
65.4 years) and 2,200 to 
placebo (mean age 65.2 
years) 
-Clarithromycin group: n = 2,172; placebo 
group: n = 2,200 
-No significant effects of clarithromycin on 
the primary outcome (344 [15.8%] vs. 307 
[13.8%], HR 1.15, 95% CI 0.99-1.34) or 
secondary outcome (249 [11.5%] vs. 218 
[9.9%], HR 1.17, 95% CI 0.98-1.40)  
-All-cause mortality (212 [9.8%] vs. 172 
[7.8%], HR 1.27, 95% CI 1.03-1.54) and CV 
mortality (111 [5.1%] vs. 78 [3.5%], HR 1.45, 
95% CI 1.09-1.92) were significantly higher 
in the clarithromycin arm  
-Age, sex, 
previous CV 
disease and risk 
factors, 
smoking status, 
concurrent use 
of certain drugs 
 
-Two-week treatment with 
clarithromycin 500 mg/day or 
matching placebo; follow-up period 
2-3 years 
-Primary outcome: composite of 
all-cause mortality, MI or unstable 
angina pectoris during 3-year 
follow-up; Secondary outcome: 
composite of CV mortality, MI or 
unstable angina pectoris 
-Limitation: more smokers were 
randomized to the clarithromycin 
arm 
24 
 
Population-Based Studies 
Asadi et 
al., 2012 
(19) 
-Population-based 
prospective cohort study of 
2,779 outpatients with 
community-acquired 
pneumonia assessed at 7 
Emergency Departments in 
Edmonton, Alberta, Canada 
prescribed macrolide (mean 
age 46.1 years) or 
fluoroquinolone (mean age 
61.9) enrolled from 
2000 to 2002 and followed 
until 2007 
-Macrolide group: n = 1,832; fluoroquinolone 
group: n = 947 
-30-day mortality was significantly lower in 
the macrolide group relative to the 
fluoroquinolone group (4 [0.2%] vs. 25 [3%], 
adjusted OR 0.28, 95% CI 0.09-0.86) 
-Age, sex, 
clinical 
radiographic 
severity of 
illness at 
presentation, 
nursing home 
status 
-10 days of any one of the 
following: doxycycline 200 mg 
initially then 100 mg/day, 
levofloxacin 500 mg/day, 
azithromycin 500 mg initially then 
250 mg/day, clarithromycin 500 
mg/day or erythromycin 500 
mg/day 
-Limitations: confounding by 
indication, physician bias, no post-
discharge microbiologic data 
available, generalizability 
20 
 
 8 
 
Chou et 
al., 2015 
(12) 
-Retrospective cohort study 
of Taiwan National Health 
Insurance data comparing 
patients prescribed oral 
amoxicillin-clavulanate 
(mean age 43.9 years), 
azithromycin (mean age 44.7 
years), clarithromycin (mean 
age 47.1 years), 
ciprofloxacin (mean age 46.9 
years), levofloxacin (mean 
age 50.6 years) or 
moxifloxacin (mean age 52.3 
years) between January 2001 
and November 2011 
-Amoxicillin-clavulanate users: n = 
1,102,358; azithromycin users: n = 66,745; 
clarithromycin users: n = 393,243; 
ciprofloxacin users: n = 205,205; levofloxacin 
users: n = 117,352; moxifloxacin users: n = 
38,833 
-Compared with amoxicillin-clavulanate 
treatment, the use of azithromycin was 
associated with significantly higher 7-day 
risks of ventricular arrhythmia (OR 4.32, 95% 
CI 2.95-6.33) and CV death (OR 2.62, 95% 
CI 1.69-4.06) 
-Compared with amoxicillin-clavulanate 
treatment, the use of clarithromycin was 
associated with similar 7-day risk of 
ventricular arrhythmia (OR 0.72, 95% CI 
0.48-1.08) and decreased risk of CV death 
(OR 0.51, 95% CI 0.33-0.80) 
-Age, sex, 
calendar date, 
concomitant 
medications, 
health resource 
utilization, 
indications for 
antibiotic use 
-Limitations: interethnic differences 
and generalizability, reliance on 
ICD-9 codes, true incidence of TdP 
unknown, residual confounding, 
confounding by indication, precise 
risk estimates for subgroups of 
patients with certain characteristics 
could not be determined 
20 
 
Mortensen 
et al., 
2014 (16) 
-Retrospective cohort study 
of VA data comparing 
31,863 patients hospitalized 
with pneumonia from 2002 
to 2012 prescribed 
azithromycin (mean age 77.8 
years) to 31,863 patients who 
received other guideline-
concordant antibiotics (mean 
age 77.8 years) 
-Azithromycin users: n = 31,863; non-
azithromycin users: n = 31,863 
-90-day mortality significantly lower in the 
azithromycin group (17.4% vs. 22.3%, OR 
0.73, 95% CI 0.70-0.76) 
-30-day mortality significantly lower in the 
azithromycin group (OR 0.76, 95% CI 0.73-
0.80) 
-Significantly increased odds of 90-day MI 
(5.1% vs. 4.4%, OR 1.17, 95% CI 1.08-1.25) 
but not any cardiac event (43.0% vs. 42.7%, 
OR 1.01, 95% CI 0.98-1.05), cardiac 
arrhythmias (25.8% vs. 26.0%, OR 0.99, 95% 
CI 0.95-1.02) or heart failure (26.3% vs. 
26.2%, OR 1.01, 95% CI 0.97-1.04) 
-Tobacco use, 
alcohol use, 
liver disease, 
multiple classes 
of medications, 
SES, race 
 
-At least 1 outpatient medication 
from a VA pharmacy within 90 
days prior to admission; at least 1 
dose of antimicrobial therapy 
within the first 48 hours of 
admission 
-Limitations: few female patients, 
only patients 65 and older, reliance 
on ICD-9 diagnosis of CV events 
rather than clinical information, 
ICD-9 codes not validated in VA 
administration data, undetermined 
duration of azithromycin therapy 
18 
Rao et al., 
2014 (9) 
-Retrospective cohort study 
of US veterans (mean age 
56.5 years) who received an 
outpatient prescription of 
-During treatment days 1 to 5, patients 
receiving azithromycin had significantly 
increased risk of death (HR 1.48, 95% CI 
1.05-2.09) and serious arrhythmia (HR 1.77, 
-Race, age, sex, 
indication for 
antibiotics 
cardiac 
-Follow-up times were separated 
into the first 5 days and days 6 
through 10 after antibiotics were 
dispensed, with day 1 being the first 
18 
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either amoxicillin (n = 
979,380), azithromycin (n = 
594,792) or levofloxacin (n = 
201,798) between September 
1999 and April 2012 
95% CI 1.20-2.62) compared with patients 
receiving amoxicillin 
-On treatment days 6 to 10, when comparing 
azithromycin with amoxicillin, risks were not 
statistically different for death from any cause 
(HR 1.14, 95% CI 0.81-1.62) and arrhythmia 
(HR 1.37, 95% CI 0.91-2.05) 
 
morbidities, 
laboratory 
findings, 
medication 
day the drug was dispensed 
-Azithromycin, levofloxacin or 
amoxicillin (including amoxicillin 
with clavulanate potassium) within 
30 days after a VA outpatient visit 
-Limitations: residual confounding, 
baseline differences between 
antibiotic groups, exclusion criteria 
Ray et al., 
2004 (10) 
-Retrospective cohort study 
of Tennessee Medicaid 
patients between January 
1988 and December 1993 
-5,305 person-years of 
current use of erythromycin 
(mean age 41.4 years) and 
111,779 person-years of 
former use (mean age 42.2 
years) compared to 
1,126,013 person-years of 
antibiotic non-use (mean age 
45.0 years) and 6,846 
person-years of current use 
of amoxicillin (mean age 
41.7 years) 
-Rate of sudden death from cardiac causes 
was twice as high among current users of 
erythromycin compared to antibiotic non-
users (10 vs. 1,358 deaths, adjusted incidence-
rate ratio 2.01, 95% CI 1.08-3.75) 
-No significant increase for former users of 
erythromycin (100 vs. 1,358 deaths, adjusted 
incidence-rate ratio 0.89, 95% CI 0.72-1.09) 
or current users of amoxicillin (8 vs. 1,358 
deaths, adjusted incidence-rate ratio 1.18, 
95% CI 0.59-2.36) 
-Smoking, 
higher BMI, 
high 
consumption of 
saturated fats, 
lack of physical 
activity, pre-
existing CV 
disease (heart 
failure, angina 
and MI), 
concurrent use 
of CYP3A4 
inhibitors 
 
-Current use: days of 
supply from the day the 
prescription was filled; antibiotic 
non-use: no use of any study 
antibiotics within the previous 365 
days; former use: some use of a 
study medication that was not 
current but had occurred within the 
previous 365 days 
-Limitations: drug compliance, no 
information on a number of 
behavioural risk factors 
19 
Ray et al., 
2012 (8) 
-Retrospective cohort study 
of Tennessee Medicaid 
patients between 1992 and 
2006 comparing patients 
who took azithromycin 
(347,795 prescriptions, mean 
age 48.6 years), no 
antibiotics (1,391,180 
prescriptions, mean age 48.6 
years), amoxicillin 
(1,348,672 prescriptions, 
mean age 47.7 years), 
ciprofloxacin (264,626 
-Increased risk of 5-day CV death (HR 2.88, 
95% CI 1.79-4.63) and death from any cause 
(HR 1.85, 95% CI 1.25-2.75) from 
azithromycin (adjusted) relative to no 
antibiotics (adjusted) 
-Relative to amoxicillin (unadjusted), 
azithromycin (adjusted) was associated with 
an increased risk of CV death (HR 2.49, 95% 
CI 1.38-4.50) and death from any cause (HR 
2.02, 95% CI 1.24-3.30) 
-Among patients who took azithromycin, 
there were 29 CV deaths during the 5-day 
course of treatment (85.2 per 1 million 
-CV disease 
and other 
behavioural risk 
factors 
associated with 
CV disease, 
indication for 
antibiotic 
therapy 
-Duration of treatment: 5-day 
period generally recommended for 
azithromycin and 10-day period 
most commonly suggested for other 
study antibiotics 
-Limitation: misclassification 
19 
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prescriptions, mean age 50.5 
years) or levofloxacin 
(193,906 prescriptions, mean 
age 51.5 years)  
courses); for those not taking antibiotics, there 
were 41 CV deaths (29.8 per 1 million 
periods); for the amoxicillin group, there were 
42 CV deaths (31.5 per 1 million courses) 
-Risk of CV death significantly greater with a 
5-day course of azithromycin (adjusted) than 
with the first 5 days of a course of 
ciprofloxacin (unadjusted HR 3.49, 95% CI 
1.32-9.26) but not significantly different from 
levofloxacin (unadjusted HR 1.27, 95% CI 
0.66-2.47) 
Schembri 
et al., 
2013 (18) 
-Secondary analysis of a 
prospectively collected 
dataset of 1,631 patients 
admitted to NHS Lothian 
Hospitals in Edinburgh, UK 
with radiologically 
confirmed community- 
acquired pneumonia and 
prescribed clarithromycin 
(median age 65 years) 
compared with patients who 
received non-macrolide 
antibiotics (median age 68 
years) during their admission 
between 2005 and 2009 
-Clarithromycin users: n = 980; non-
macrolide users: n = 651 
-Significant association between 
clarithromycin use and CV events compared 
with non-macrolide users after propensity 
matching (123 [12.6%] vs. 48 [7.4%], HR 
1.58, 95% CI 1.08-2.30) 
-Clarithromycin use was not associated with a 
significant difference in all-cause mortality 
(adjusted HR 1.13, 95% CI 0.85-1.51) or CV 
mortality (adjusted HR 1.58, 95% CI 0.93-
2.71) 
-Age, history of 
CV events 
-Macrolide users included all 
patients who received at least one 
dose of clarithromycin during their 
hospital admission 
-Duration of use: < 3 days, 3-6 
days, 7 days, > 7 days 
-1-year follow-up 
-Limitations: bias due to 
unrecorded factors, patients with 
more severe illness were more 
likely to be prescribed 
clarithromycin and thus 
clarithromycin may be a marker for 
more severe infection and hence 
increased CV events 
16 
Svanstrom 
et al., 
2013 (17) 
-Retrospective cohort study 
of Danish adults comparing 
1,102,050 episodes of 
azithromycin use (mean age 
39.7 years) with no use of 
antibiotic (mean age 39.5 
years) matched in a 1:1 ratio 
and comparing 1,102,419 
episodes of azithromycin use 
(mean age 39.7 years) with 
7,364,292 episodes of 
-With propensity score matched analysis, risk 
of death from CV causes significantly 
increased with current use of azithromycin as 
compared with no use of antibiotics (rate ratio 
2.85, 95% CI 1.13-7.24) 
-With adjustment for propensity scores, 
current azithromycin use was not associated 
with an increased risk of CV death when 
compared with penicillin V (rate ratio 0.93, 
95% CI 0.56-1.55)  
-Age, sex, 
history of CV 
disease 
 
-Current use (1-5 days), recent use 
(6-10 days) and past use (11-35 
days) 
-Limitations: no information on the 
indication for treatment and several 
known risk factors (e.g. smoking 
and BMI), primary definition, 
including all CV causes of death, 
was broad 
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penicillin V use (mean age 
42.0 years) between 1997 
and 2010 
Svanstrom 
et al., 
2014 (37) 
-Retrospective cohort study 
of Danish adults who 
received prescriptions for 
clarithromycin (n = 108,767, 
mean age 57.2 years), 
roxithromycin (n = 350,575, 
mean age 56.6 years) or 
penicillin V (n = 1,519,324, 
mean age 55.7 years) 
-Compared with use of penicillin V (235 
deaths, incidence rate 2.5 per 1,000 person 
years), use of clarithromycin was associated 
with a significantly increased risk of cardiac 
death (18 deaths, incidence rate 5.3 per 1,000 
person years, adjusted rate ratio 1.76, 95% CI 
1.08-2.85) but use of roxithromycin was not 
(32 deaths, incidence rate 2.5 per 1,000 
person years, adjusted rate ratio 1.04, 95% CI 
0.72-1.51) 
-Sex, age, 
cardiac risk 
score, 
concomitant 
use of 
cytochrome 
P450 3A 
inhibiting drugs 
-Treatment: 7-day course of 
antibiotic 
-Limitations: lack of information on 
lifestyle and health factors known 
to influence the risk of cardiac 
death (e.g. smoking and BMI), 
missing infection information, 
limited power to detect difference 
in subgroup analyses 
16 
 
Abbreviations: BMI = body mass index, CI = confidence interval, CV = cardiovascular, HR = hazard ratio, ICD-9 = International Classification of Diseases, 
Ninth Revision, IL = interleukin, MI = myocardial infarction, NHS = National Health Service, OR = odds ratio, SES = socioeconomic status, TdP = torsades de 
pointes, TNF = tumour necrosis factor, VA = Department of Veterans Affairs 
aWe evaluated the quality of individual studies using the Downs and Black quality assessment method, which is a list of 27 criteria to evaluate both randomized 
and non-randomized trials (Appendix A) (36). This scale assesses the completeness and clarity of study reporting, external validity, internal validity (e.g. bias and 
confounding) and power. The tool was modified slightly for use in our review. Specifically, the scoring for question 27 dealing with statistical power was 
simplified to a choice of awarding either 1 or 0 points depending on whether there was sufficient power to detect a clinically important effect. On the modified 
scale, we gave all included studies a score from 0 to 28, grouped into the following four quality levels: excellent (26 to 28), good (20 to 25), fair (15 to 19) and 
poor (14 or less). 
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Chapter 3  
3 Rationale and Research Questions 
 
3.1 The need for research 
In 2013, Health Canada and the U.S. FDA warned about a higher risk of QT interval 
prolongation and subsequent ventricular arrhythmia among patients taking azithromycin 
(6,7). Although many case reports support this assertion (13–15,27), evidence from 
published studies is inconsistent (8–12,16–19,37). To better elucidate the safety profiles 
of macrolide antibiotics in the treatment of community-acquired respiratory tract 
infections, we conducted a population-based cohort study to investigate the risks of 
ventricular arrhythmia and all-cause mortality associated with azithromycin, 
clarithromycin or erythromycin use compared with other antibiotics for similar 
indications.  
 
3.2 Research questions and hypotheses 
3.2.1 Primary research question 
In the outpatient setting, does a group of patients prescribed macrolide antibiotics 
compared with a group of patients prescribed non-macrolide antibiotics that have similar 
baseline characteristics have an altered 30-day risk of a hospital encounter with 
ventricular arrhythmia? 
Hypothesis:  Based on prior literature, macrolide antibiotic use may be associated with a 
higher risk of ventricular arrhythmia compared with non-macrolide antibiotic use. 
However, based on other prior literature, it is also possible that there will be no difference 
in risk between the two groups.  
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3.2.2 Secondary research questions 
1) In the outpatient setting, does a group of patients prescribed macrolide antibiotics 
compared with a group of patients prescribed non-macrolide antibiotics that have 
similar baseline characteristics have an altered 30-day risk of all-cause mortality? 
Hypothesis:  Based on prior literature, macrolide antibiotic use may be associated 
with a higher risk of all-cause mortality compared with non-macrolide antibiotic use. 
However, based on other prior literature, it is also possible that there will be no 
difference in risk between the two groups.  
2) In older adults in the outpatient setting, in subgroup analyses is the association 
between macrolide antibiotic use (compared with non-macrolide antibiotic use) and 
30-day risk of a hospital encounter with ventricular arrhythmia modified in the 
presence of conditions that can be responsible for ventricular arrhythmia? These four 
conditions are (1) chronic kidney disease, (2) congestive heart failure, (3) coronary 
artery disease and (4) concurrent use of a drug known to prolong the QT interval. 
Hypothesis:  Compared with non-macrolide antibiotic use, macrolide antibiotic use 
will be associated with a higher risk of ventricular arrhythmia when the conditions 
that can be responsible for ventricular arrhythmia are present.  
3) In older adults in the outpatient setting, in subgroup analyses is the association 
between macrolide antibiotic use (compared with non-macrolide antibiotic use) and 
30-day risk of all-cause mortality modified in the presence of conditions that can be 
responsible for mortality? These four conditions are (1) chronic kidney disease, (2) 
congestive heart failure, (3) coronary artery disease and (4) concurrent use of a drug 
known to prolong the QT interval. 
Hypothesis:  Compared with non-macrolide antibiotic use, macrolide antibiotic use 
will be associated with a higher risk of all-cause mortality when the conditions that 
can be responsible for mortality are present.  
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Chapter 4  
4 Methods 
 
4.1 Study design and setting 
We conducted a population-based retrospective cohort study of older adults from  
April 1, 2002 to March 1, 2013 using linked healthcare databases in Ontario, Canada. 
Ontario has approximately 13.7 million residents, 16% of whom are 65 years of age or 
older (38). The Ontario Health Insurance Plan (OHIP) is the single payer for all Ontario 
citizens and provides universal access to hospital care and physician services. Those aged 
65 years or older (approximately 2 million residents) also receive prescription drug 
coverage.  
Ontario’s administrative healthcare databases provide a rich source of information and 
are representative of the entire province. The use of these databases addresses problems 
typical of prospective studies, such as selection and information biases, and allow for 
large sample sizes and long periods of follow-up. Emigration out of Ontario is less than 
1% per year, with little loss to follow-up (39).  
We conducted this study at the Institute for Clinical Evaluative Sciences (ICES) 
according to a pre-specified protocol that was approved by the Research Ethics Board at 
Sunnybrook Health Sciences Centre (Toronto, Ontario). Participant informed consent 
was not required for this study. The reporting of this study followed the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) guidelines (see 
Appendix B) (40). 
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4.2 Data sources 
We used the following 11 healthcare administrative databases housed at ICES to 
ascertain patient characteristics, drug exposure, covariate information and outcome data. 
These datasets were linked using unique, encoded identifiers and analyzed at ICES.  
Registered Persons Database of Ontario (RPDB):  We used RPDB to obtain information 
on patient demographics (age, sex and vital status), income (categorized into quintiles of 
average neighbourhood income) and location of residence (urban or rural). Moreover, we 
used the vital status information captured by this database to ascertain the outcome of  
all-cause mortality. 
Ontario Drug Benefit (ODB) Database:  The ODB database stores records for all 
outpatient drug prescriptions dispensed to patients aged 65 years and older in Ontario 
with a high level of accuracy (overall error rate of less than 1%) (41). We used this 
database to ascertain exposure to macrolide antibiotics and baseline medication use 
assessed in the 120 days prior to cohort entry. We also acquired information on patient 
residential status (community-dwelling or long-term care) and medical specialty of the 
physicians who prescribed study antibiotics. 
Canadian Institute for Health Information Discharge Abstract Database and National 
Ambulatory Care Reporting System (CIHI-DAD, NACRS):  CIHI-DAD and NACRS 
contain diagnostic and procedural information on all inpatient, emergency department 
and outpatient visits occurring in Ontario. The hospital diagnosis codes were based on the 
International Classification of Diseases, Ninth Revision (ICD-9) codes prior to 2002 and 
Tenth Revision (ICD-10) codes since 2002. We used both ICD-9 and ICD-10 codes to 
determine baseline comorbidities in the five years prior to receipt of the new antibiotic 
prescription (detailed in Appendix C). We used ICD-10 codes exclusively to determine 
hospitalized outcomes since all events occurred after the implementation of this coding 
system (detailed in Appendix D). 
Ontario Health Insurance Plan (OHIP) Database:  The OHIP database contains 
information on physician claims for inpatient and outpatient services using fee codes. We 
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used the information captured by this database to identify baseline comorbid conditions 
in addition to the diagnostic information obtained from CIHI-DAD.  
Canadian Organ Replacement Register (CORR):  This registry stores information on 
renal replacement therapies. CORR receives data from the Ontario Renal Network, 
Trillium Gift of Life Network and independent sources. We used this database to identify 
the number of kidney transplants occurring in our cohort for the comorbidity of chronic 
kidney disease. 
Ontario Mental Health Reporting System (OMHRS) Database:  The OMHRS database 
contains demographic and health information on patients admitted to adult mental health 
beds in Ontario. Diagnosis codes for health conditions based on the Diagnostic and 
Statistical Manual of Mental Disorders, 4th Edition are recorded in this database (detailed 
in Appendix C). In addition to the CIHI-DAD and OHIP databases, we used the 
diagnostic information stored in this database to determine baseline psychiatric comorbid 
conditions. 
Institute for Clinical Evaluative Sciences Physician Database (IPDB):  IPDB reports 
prescriber and specialist referral data including demographics, education, location and 
measures of physician activity. We used this database to measure the number of general 
practitioner visits and nephrologist and cardiologist consults. 
Ontario Registrar General Vital Statistics Database (ORGD):  ICD-9 codes were used to 
ascertain cause of death in ORGD (see Appendix E). New variables that are coded in the 
database as ICD-10 are converted to ICD-9 codes to ensure consistency across all years. 
Cerner and Gamma-Dynacare Laboratory Databases:  A subpopulation of patients in 
Southwestern Ontario had outpatient serum creatinine and urine dipstick protein 
measurements available before cohort entry and was in the catchment area of 12 hospitals 
in which linked serum creatinine laboratory measurements were available through these 
laboratory datasets. We used the information to assess baseline kidney function. 
All 11 databases have been used previously to study adverse drug events and health 
outcomes (42–51). 
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4.3 Patients 
We established a cohort of older adults in Ontario who were dispensed a new outpatient 
prescription for a macrolide antibiotic (azithromycin, clarithromycin or erythromycin) 
between April 1, 2002 and March 1, 2013. The date of the prescription served as the 
index date (referred to as the cohort entry date or start time for follow-up).  
Inherent to observational drug studies is a bias known as confounding by indication. This 
bias occurs when drugs are selectively used or not used by those who developed the 
outcome of interest (52). The assumption is that patients are exposed to drugs for 
particular reasons and the variables underlying these reasons may predispose patients to 
study outcomes of interest. A method to limit confounding by indication is to compare 
treatments that are interchangeable within the same indication (53). Therefore, we 
compared our macrolide antibiotic users to a group of older adults with similar indicators 
of baseline health who were prescribed non-macrolide antibiotics (amoxicillin, 
cefuroxime or levofloxacin).  
Before matching, we excluded the following patients from both groups: (1) those who 
were in their first year of eligibility for prescription drug coverage (aged 65 years) to 
avoid incomplete medication records, (2) those with prescriptions for any antibiotic in the 
180 days prior to the index date to ensure that the drug was newly prescribed, (3) those 
who received a prescription for more than one type of antibiotic on the index date (in 
order to form mutually exclusive groups), (4) those who were discharged from the 
hospital in the two days prior to their index date to ensure these were new outpatient 
antibiotic prescriptions (because in Ontario, patients continuing an antibiotic treatment 
initiated in the hospital would have their outpatient antibiotic prescription dispensed on 
the same day or the day after hospital discharge) and (5) those with daily drug doses that 
were not standard for the treatment of respiratory tract infections to ensure 
generalizability to usual prescribing (see Appendix F). Study patients could only enter the 
cohort once, so for patients with multiple eligible prescriptions, we restricted the 
information to the first eligible prescription. 
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4.4 Matching 
We used propensity score matching to eliminate systematic differences in the measured 
baseline characteristics of our comparison groups. This allowed us to form a matched set 
of patients in our two groups with a similar probability of receiving a macrolide antibiotic 
given a set of measured baseline covariates (54,55). We estimated the propensity scores 
using a multivariable logistic regression model with 106 baseline characteristics selected 
because of their potential influence on the outcomes or segregation of patients between 
the comparison groups (Appendix G) (55–57). Subsequently, we matched a referent user 
to each macrolide antibiotic user on the following six characteristics: the logit of the 
propensity score (within calipers of width ± 0.2 standard deviations) (58), chronic kidney 
disease (yes or no), congestive heart failure (yes or no), coronary artery disease (yes or 
no), QT-prolonging drug use (yes or no) and availability of serum creatinine 
measurement in the year prior to the index date (yes or no). There are several types of 
matching techniques including individual matching and frequency matching (59). In 
greedy matching, a macrolide antibiotic user is first selected at random and then matched 
to the nearest non-macrolide antibiotic user, even if that non-user would have been a 
better match for a subsequent macrolide antibiotic user. This process is then repeated 
until non-macrolide antibiotic users have been matched to all macrolide antibiotic users 
or until the list of macrolide antibiotic users for whom a matched non-macrolide 
antibiotic user can be found has been exhausted (55). An alternative to greedy matching 
is optimal matching, in which matches are formed to minimize the total within-pair 
difference of the propensity score (60). In studies involving large administrative 
healthcare databases, greedy matching is simpler to implement and considerably faster to 
run. Additionally, it has been shown that optimal matching does not perform better than 
greedy matching in forming balanced groups (61). For these reasons, we selected the 
greedy matching technique. Study patients were matched without replacement. Those 
who were not matched successfully were excluded from our analysis.  
We anticipated the 106 variables used in this study to be complete. We expected 
prescriber information would be missing in up to 25% of patients based on the results of 
prior studies (42,46,51,62). For income quintile, we expected up to 0.5% of patients 
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would have a missing value based on the results of prior studies (42,46,62), and missing 
values in the unmatched cohort were re-classified into the average income quintile 
(income quintile 3) during matching. For location of residence, we expected up to 0.2% 
of patients would have a missing value based on the results of prior studies (49,51), and 
missing values in the unmatched cohort were re-classified into the "No" category during 
matching.  
 
4.5 Baseline characteristics 
We assessed baseline comorbid conditions in the five years prior to the index date and 
concurrent medication use in the 120 days prior to the index date of each macrolide 
antibiotic user and referent non-macrolide antibiotic user (see Appendix C for coding 
information). For the subpopulation of patients whose laboratory measurements were 
available, we assessed their kidney function in the year prior to their index date. Chest x-
ray, urinalysis and sputum tests were assessed in the seven days prior to cohort entry. We 
evaluated prior health care use with physician visits, and diagnostic and screening tests 
performed in the previous year. 
 
4.6 Outcomes 
The primary outcome of this study was a hospital encounter (presentation to the 
emergency room or hospital admission) with ventricular arrhythmia (ventricular 
tachycardia or ventricular fibrillation) in any diagnosis field. The secondary outcome was 
all-cause mortality. We restricted our analysis to 30 days after the index date because 
macrolide antibiotics are prescribed for short durations and any observed outcomes can 
be reasonably attributed to our study drugs over this timeframe. Furthermore, QT interval 
prolongation has been shown to start within hours to days of initiating macrolides, and 
thus, one would expect that drug-related ventricular arrhythmias would occur soon after 
initiating a macrolide antibiotic prescription (14,15,63–65). 
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The diagnosis codes used to identify ventricular arrhythmia are presented in Appendix D. 
Trained personnel enter these codes into the databases based only on physician-recorded 
diagnoses in a patient’s medical chart. The ICD-10 codes for ventricular arrhythmia have 
not been fully validated; however, we would expect their sensitivity to be low as true 
ventricular arrhythmias frequently go undetected in routine healthcare (because they 
often occur outside hospital settings, in unmonitored patients in hospital or in a setting of 
multi-organ medical illness). In previous studies assessing the accuracy of ICD-9 and 
ICD-10 codes for cardiac arrhythmia (ventricular and supraventricular), the positive 
predictive value (PPV; truly have the condition when code present) exceeded 80% (66–
69). We performed a manual review of 202 charts in our region and confirmed a PPV of 
92% (95% CI 87-95%) for the set of codes used in this study to detect ventricular 
arrhythmia. All-cause mortality vital statistics are coded accurately in our data sources 
with a sensitivity of 97.8% and specificity of 100% for the finding of death (70). 
 
4.7 Statistical analyses 
We compared baseline characteristics between those prescribed macrolide antibiotics and 
those prescribed non-macrolide antibiotics using standardized differences. This metric 
describes differences between group means relative to the pooled standard deviation and 
is considered a meaningful difference if greater than 10% (71). The use of standardized 
differences is preferred over statistical hypothesis testing (using P values) for assessing 
balance in baseline characteristics between propensity score matched groups (72–74). 
The standardized difference is not influenced by sample size and thus, one can compare 
balance in the unmatched sample to that in the matched sample (73,74).  
We estimated the OR and 95% CIs for the primary and secondary outcomes using 
conditional logistic regression, which accounted for matching (75). The non-macrolide 
antibiotic group was the referent group. Each OR was approximated to be the relative risk 
(RR), which was appropriate given the incidences observed.  
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We also evaluated the association between macrolide antibiotic and our outcomes in four 
specified subgroups, defined by the presence or absence of the following conditions: (1) 
chronic kidney disease, (2) congestive heart failure, (3) coronary artery disease and (4) 
concurrent use of a drug known to prolong the QT interval (Appendix H). We 
hypothesized that any RR of ventricular arrhythmia with macrolide antibiotic use 
compared to referent antibiotic might be greater when these conditions were present than 
when they were absent. For example, the dose of clarithromycin should be reduced by 
50% in chronic kidney disease due to impaired clearance, but in practice this seldom 
occurs (76). Similarly, in prior reports, ventricular arrhythmia with macrolide antibiotic 
use frequently occurred in patients with pre-existing risk factors such as congestive heart 
failure (77), cardiovascular disease (14,78–80) and those taking other QT-prolonging 
medications (81,82). We determined interaction P values by including interaction terms 
in the regression models.  
Chronic kidney disease was identified using an algorithm of hospital diagnosis codes 
validated in our region for older adults (83). The algorithm identified patients with a 
median estimated glomerular filtration rate (eGFR) of 38 mL/min/1.73 m2 (interquartile 
range [IQR] 27-52 mL/min/1.73 m2), whereas its absence identified patients with a 
median eGFR of 69 mL/min/1.73 m2 (IQR 56-82 mL/min/1.73 m2). The algorithm for 
chronic kidney disease had a sensitivity of 32% and specificity of 94% using an eGFR of 
45 mL/min/1.73 m2 as the reference standard (83). Due to its limited sensitivity, the 
algorithm underestimated the true prevalence of chronic kidney disease. 
To provide insights for any observed difference in all-cause mortality between our two 
groups, we also conducted a post hoc analysis to determine the various causes of death in 
our matched cohort. Finally, we conducted an additional analysis of our outcomes at 14 
days of follow-up rather than 30 days.  
We conducted all analyses with SAS version 9.4 (SAS Institute, Cary, North Carolina, 
2011). In all outcome analyses, we interpreted two-tailed P values less than 0.05 as 
statistically significant. 
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Chapter 5  
5 Results 
 
5.1 Cohort characteristics 
5.1.1 Unmatched cohort 
Cohort selection is presented in Figure 1 and baseline characteristics before and after 
matching are presented in Table 2. We identified 616,359 older adults with prescriptions 
for macrolide antibiotics (azithromycin, clarithromycin or erythromycin) and 705,132 
patients with prescriptions for the referent antibiotics (amoxicillin, cefuroxime or 
levofloxacin) before matching. The mean age of the unmatched cohort was 73.9 years 
and 56.7% were women.  
Prior to matching, patients prescribed macrolide antibiotics compared to those prescribed 
referent antibiotics were more likely to receive their prescription from a general 
practitioner (77.0% vs. 56.6%), have chronic lung disease (28.8% vs. 23.8%), were less 
likely to use warfarin (4.6% vs. 7.4%) and were less likely to have a urinalysis test (1.5% 
vs. 4.9%) (Table 2). Information on income was not available for 2,160 (0.4%) macrolide 
antibiotic users and 2,468 (0.4%) non-macrolide antibiotic users. Location of residence 
could not be ascertained for 647 (0.1%) macrolide antibiotic users and 708 (0.1%)  
non-macrolide antibiotic users. Local Health Integration Network (LHIN), which refers 
to health authorities responsible for regional administration of public healthcare services 
in Ontario, was unavailable for 619 (0.1%) macrolide antibiotic users and 684 (0.1%) 
non-macrolide antibiotic users. Prescriber information was not available for 100,111 
(16.2%) macrolide antibiotic users and 262,915 (37.3%) non-macrolide antibiotic users in 
the unmatched cohort. 
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5.1.2 Matched cohort 
A total of 503,612 macrolide antibiotic users were successfully matched to 503,612  
non-macrolide antibiotic users. The two groups were well-balanced and showed no 
meaningful differences in the 106 measured baseline characteristics: age, sex, income, 
year of cohort entry, location of residence, residential status, LHIN, prescribing 
physician, 30 comorbid conditions, use of 37 medications, general practitioner visits, 
nephrology consults, cardiology consults, 25 prior investigations and treatments, baseline 
serum creatinine concentration, eGFR and urine dipstick protein (Table 2). The mean age 
of the matched cohort was 74.0 years and 57.3% of patients were women. Clarithromycin 
and azithromycin were the most frequently prescribed macrolide antibiotics (48.4% and 
48.3%, respectively), followed by erythromycin (3.3%). The median starting daily dose 
for clarithromycin was 1,000 mg (IQR 500 to 1,000 mg), for azithromycin was 300 mg 
(IQR 300 to 300 mg) and for erythromycin was 1,000 mg (IQR 999 to 1,000 mg). The 
median day supply for clarithromycin, azithromycin and erythromycin was 10 days (IQR 
7 to 10 days), 5 days (IQR 5 to 5 days) and 7 days (IQR 7 to 10 days), respectively. 
LHIN information was unavailable for 500 (0.1%) macrolide users and 480 (0.1%) non-
macrolide antibiotic users in the matched cohort. Prescriber information was not available 
for 100,093 (19.9%) macrolide antibiotic users and 95,973 (19.1%) non-macrolide 
antibiotic users in the matched cohort. General practitioners were the most frequent 
prescribers (73.1%).  
 
5.2 Main analysis 
The primary and secondary outcomes are shown in Table 3. Across the entire cohort, in 
the 30-day follow-up period, 260 patients (0.03%) had a record of a hospital encounter 
with ventricular arrhythmia and 6,977 (0.69%) died. 
The 30-day risk of ventricular arrhythmia with macrolide antibiotic use compared to 
referent antibiotic use was not statistically different (0.03% vs. 0.03%, RR 1.06, 95% CI 
0.83-1.36, P value 0.62). Macrolide antibiotic compared with referent antibiotic was 
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associated with a lower 30-day risk of all-cause mortality (0.62% vs. 0.76%, RR 0.82, 
95% CI 0.78-0.86, P value < 0.0001). 
 
5.3 Subgroup analysis 
Subgroup analyses for ventricular arrhythmia and all-cause mortality are shown in 
Figures 2 and 3. The presence or absence of chronic kidney disease, congestive heart 
failure, coronary artery disease or concurrent use of a QT-prolonging drug did not 
significantly modify the relative association between antibiotic exposure and the risk of 
ventricular arrhythmia (P values for interaction ranged from 0.28-0.80). Across all 
subgroups, use of macrolide antibiotics compared to referent antibiotics was associated 
with a lower risk of all-cause mortality, with no modification of the relative association 
across subgroups (P values for interaction ranged from 0.11-0.67). 
 
5.4 Additional analyses 
First, using ORGD, we conducted a post hoc analysis to determine the various causes of 
death in our matched cohort. Specific codes are listed in Appendix E. There were no 
significant differences in the cause of death between the two groups. The most common 
cause of 30-day mortality among older adults prescribed macrolide antibiotics was 
cardiovascular disease (n = 638, 20.3% of deaths), followed by cancer (n = 569, 18.1%). 
Among older adults prescribed referent antibiotics, the most common causes of death 
were cancer (n = 785, 20.5%) and cardiovascular disease (n = 755, 19.7%) (Appendix I).  
 
Second, we examined our outcomes at 14 days of follow-up. Similar to our 30-day 
follow-up analysis, macrolide antibiotic use compared to referent antibiotic use was 
associated with no different risk in ventricular arrhythmia (0.01% vs. 0.01%, RR 0.99, 
95% CI 0.71-1.37, P value 0.93) and a lower risk of all-cause mortality (0.34% vs. 
0.41%, RR 0.82, 95% CI 0.77-0.87, P value < 0.0001) (Appendix J).  
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Ontario residents who were prescribed a new outpatient oral macrolide antibiotic 
(azithromycin, clarithromycin or erythromycin) or non-macrolide antibiotic 
(amoxicillin, cefuroxime or levofloxacin) between April 1, 2002 and March 1, 2013  
(n = 1,726,846) 
Patients excluded from study (n = 405,355) 
   Patients who died on or before the index date: 893 
   Patients <66 years on index date: 95,425 
   Prescriptions for any antibiotic in the 180 days    
      prior to the index date or evidence of two  
      different drug classes on the index date: 230,404 
   Discharged from a hospital in the two days prior  
      to the index date: 24,660 
   Atypical daily dose of study antibiotic: 53,973 
Macrolide and non-macrolide antibiotic users following exclusions (n = 1,321,491) 
Propensity score matching 
Unmatched (n = 314,267) 
   Macrolides: 112,747 
   Non-macrolides: 201,520 
Macrolide antibiotic users  
(n = 503,612) 
Non-macrolide antibiotic users  
(n = 503,612) 
Macrolide antibiotic users  
(n = 616,359) 
Non-macrolide antibiotic users  
(n = 705,132) 
Figure 1. Flow diagram of cohort selection 
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Table 2. Baseline characteristics of macrolide antibiotic (azithromycin, clarithromycin or erythromycin) users and non-macrolide 
antibiotic (amoxicillin, cefuroxime or levofloxacin) users pre- and post-matcha 
 
Variable 
Unmatched Matched 
Macrolide 
(n = 616,359) 
Non-Macrolide 
(n = 705,132) 
Standardized  
Differenceb 
Macrolide 
(n = 503,612) 
Non-Macrolide 
(n = 503,612) 
Standardized 
Differenceb 
Demographics 
  Age, mean (SD), years 73.7 (7.1) 74.1 (7.3) 6% 73.9 (7.2) 74.0 (7.2) 2% 
  Women 359,895 (58.4) 389,520 (55.2) 6% 288,515 (57.3) 288,473 (57.3) 0% 
  Income quintilec 
    1 (low) 120,433 (19.5) 135,873 (19.3) 1% 99,340 (19.7) 100,535 (20.0) 1% 
    2 128,791 (20.9) 147,680 (20.9) 0% 106,101 (21.1) 106,738 (21.2) 0% 
    3 (middle) 121,353 (19.7) 139,156 (19.7) 0% 101,012 (20.1) 101,455 (20.1) 0% 
    4 120,224 (19.5) 138,126 (19.6) 0% 97,895 (19.4) 97,247 (19.3) 0% 
    5 (high) 123,398 (20.0) 141,829 (20.1) 0% 99,264 (19.7) 97,637 (19.4) 1% 
  Year of cohort entry 
    2002 71,875 (11.7) 71,491 (10.1) 5% 56,548 (11.2) 56,434 (11.2) 0% 
    2003 89,014 (14.4) 86,440 (12.3) 6% 69,300 (13.8) 68,989 (13.7) 0% 
    2004 70,341 (11.4) 71,392 (10.1) 4% 55,248 (11.0) 55,193 (11.0) 0% 
    2005 63,839 (10.4) 66,701 (9.5) 3% 50,803 (10.1) 51,007 (10.1) 0% 
    2006 51,400 (8.3) 59,498 (8.4) 0% 42,229 (8.4) 42,502 (8.4) 0% 
    2007 46,988 (7.6) 55,608 (7.9) 1% 38,824 (7.7) 38,995 (7.7) 0% 
    2008 46,180 (7.5) 54,246 (7.7) 1% 37,802 (7.5) 37,898 (7.5) 0% 
    2009 41,919 (6.8) 53,244 (7.6) 3% 35,205 (7.0) 35,175 (7.0) 0% 
    2010 42,552 (6.9) 55,593 (7.9) 4% 35,973 (7.1) 35,860 (7.1) 0% 
    2011 41,502 (6.7) 58,617 (8.3) 6% 36,529 (7.3) 36,470 (7.2) 0% 
 27 
 
 
    2012 41,276 (6.7) 60,475 (8.6) 7% 37,075 (7.4) 37,011 (7.3) 0% 
    2013 9,473 (1.5) 11,827 (1.7) 1% 8,076 (1.6) 8,078 (1.6) 0% 
  Rural residenced 87,490 (14.2) 89,820 (12.7) 4% 68,952 (13.7) 67,861 (13.5) 1% 
  Long-term care 20,921 (3.4) 37,020 (5.3) 9% 20,538 (4.1) 23,129 (4.6) 3% 
  LHINe 
    1 35,679 (5.8) 36,429 (5.2) 3% 29,201 (5.8) 27,684 (5.5) 1% 
    2 48,731 (7.9) 56,169 (8.0) 0% 39,542 (7.9) 40,003 (7.9) 0% 
    3 30,062 (4.9) 32,784 (4.6) 1% 24,531 (4.9) 22,812 (4.5) 2% 
    4 75,103 (12.2) 95,783 (13.6) 4% 61,236 (12.2) 68,781 (13.7) 4% 
    5 28,553 (4.6) 36,298 (5.1) 2% 23,584 (4.7) 26,199 (5.2) 2% 
    6 43,184 (7.0) 52,734 (7.5) 2% 35,609 (7.1) 36,197 (7.2) 0% 
    7 49,886 (8.1) 61,560 (8.7) 2% 40,894 (8.1) 43,485 (8.6) 2% 
    8 74,884 (12.1) 88,508 (12.6) 1% 61,529 (12.2) 61,848 (12.3) 0% 
    9 71,866 (11.7) 88,861 (12.6) 3% 58,702 (11.7) 64,162 (12.7) 3% 
    10 30,641 (5.0) 32,286 (4.6) 2% 24,907 (4.9) 22,293 (4.4) 2% 
    11 60,098 (9.8) 58,581 (8.3) 5% 49,208 (9.8) 41,608 (8.3) 5% 
    12 23,560 (3.8) 24,074 (3.4) 2% 18,914 (3.8) 17,158 (3.4) 2% 
    13 31,464 (5.1) 30,400 (4.3) 4% 25,408 (5.0) 23,275 (4.6) 2% 
    14 12,029 (2.0) 9,981 (1.4) 4% 9,847 (2.0) 7,627 (1.5) 3% 
Prescribing physicianf 
  General practitioner 474,660 (77.0) 398,920 (56.6) 44% 367,302 (72.9) 368,847 (73.2) 1% 
  Internist 2,797 (0.5) 2,967 (0.4) 1% 2,461 (0.5) 2,611 (0.5) 0% 
  Nephrologist 802 (0.1) 788 (0.1) 1% 749 (0.1) 626 (0.1) 1% 
  Cardiologist 856 (0.1) 1,146 (0.2) 1% 813 (0.2) 909 (0.2) 0% 
  Other 37,133 (6.0%) 38,396 (5.4) 2% 32,194 (6.4) 34,646 (6.9) 2% 
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Comorbiditiesg 
  Dementia 46,958 (7.6) 68,671 (9.7) 8% 42,887 (8.5) 45,532 (9.0) 2% 
  Schizophrenia or other  
  psychotic disorders 12,614 (2.0) 17,771 (2.5) 3% 11,363 (2.3) 11,985 (2.4) 1% 
  Bipolar disorder 9,964 (1.6) 12,986 (1.8) 2% 8,645 (1.7) 8,764 (1.7) 0% 
  Unipolar depression    
  and/or anxiety disorder 46,254 (7.5) 53,089 (7.5) 0% 38,397 (7.6) 38,481 (7.6) 0% 
  Haemorrhagic stroke  1,056 (0.2) 1,556 (0.2) 1% 957 (0.2) 990 (0.2) 0% 
  Ischemic stroke  6,544 (1.1) 9,804 (1.4) 3% 6,005 (1.2) 6,366 (1.3) 1% 
  TIA 2,545 (0.4) 3,475 (0.5) 1% 2,263 (0.4) 2,363 (0.5) 0% 
  Chronic liver disease 19,210 (3.1) 23,094 (3.3) 1% 16,167 (3.2) 16,299 (3.2) 0% 
  Chronic kidney diseaseh 27,800 (4.5) 36,539 (5.2) 3% 25,543 (5.1) 25,543 (5.1) 0% 
  Congestive heart failure 61,351 (10.0) 77,802 (11.0) 4% 56,214 (11.2) 56,214 (11.2) 0% 
  Coronary artery diseasei 158,521 (25.7) 190,688 (27.0) 3% 138,038 (27.4) 138,038 (27.4) 0% 
  Angina 117,261 (19.0) 135,415 (19.2) 0% 99,400 (19.7) 99,463 (19.7) 0% 
  Peripheral vascular  
  disease 8,365 (1.4) 10,267 (1.5) 1% 7,422 (1.5) 7,537 (1.5) 0% 
  Parkinson's disease 8,858 (1.4) 13,096 (1.9) 3% 7,995 (1.6) 8,289 (1.6) 0% 
  Chronic lung disease 177,653 (28.8) 167,962 (23.8) 11% 138,346 (27.5) 136,245 (27.1) 1% 
  Atrial fibrillation/flutter 25,513 (4.1) 39,678 (5.6) 7% 23,970 (4.8) 25,574 (5.1) 1% 
  Cancerj 76,143 (12.4) 86,596 (12.3) 0% 62,477 (12.4) 62,302 (12.4) 0% 
  Alcoholism 3,578 (0.6) 4,757 (0.7) 1% 3,187 (0.6) 3,263 (0.6) 0% 
  Seizure 3,058 (0.5) 4,290 (0.6) 2% 2,772 (0.6) 2,936 (0.6) 0% 
  Acute kidney injury  6,238 (1.0) 9,090 (1.3) 3% 5,849 (1.2) 6,079 (1.2) 0% 
  Acute myocardial  
  infarction  18,673 (3.0) 23,811 (3.4) 2% 16,863 (3.3) 16,947 (3.4) 0% 
  Pacemaker  23,606 (3.8) 31,405 (4.5) 3% 21,185 (4.2) 21,497 (4.3) 0% 
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  Hospitalization with  
  hyperkalemia 2,607 (0.4) 3,358 (0.5) 1% 2,374 (0.5) 2,422 (0.5) 0% 
  Hypotension 6,289 (1.0) 8,542 (1.2) 2% 5,661 (1.1) 5,838 (1.2) 0% 
  Prostatic hyperplasia 72,621 (11.8) 90,528 (12.8) 3% 61,284 (12.2) 61,487 (12.2) 0% 
  Prostatitis 28,193 (4.6) 33,028 (4.7) 1% 23,411 (4.6) 23,426 (4.7) 0% 
  Acute urinary retention 7,970 (1.3) 10,869 (1.5) 2% 7,068 (1.4) 7,248 (1.4) 0% 
  DVT/PE 942 (0.2) 1,611 (0.2) 2% 892 (0.2) 1,005 (0.2) 1% 
  Charlson comorbidity indexk 
    0 394,182 (64.0) 441,541 (62.6) 3% 396,258 (78.7) 394,517 (78.3) 1% 
    1 151,182 (24.5) 173,421 (24.6) 0% 44,718 (8.9) 45,227 (9.0) 0% 
    2 36,695 (6.0) 44,093 (6.3) 1% 31,456 (6.2) 31,689 (6.3) 0% 
    ≥ 3 34,300 (5.6) 46,077 (6.5) 4% 31,180 (6.2) 32,179 (6.4) 1% 
  Johns Hopkins Aggregated Diagnosis Groups 
    0 14,708 (2.4) 18,706 (2.7) 2% 12,004 (2.4) 11,646 (2.3) 0% 
    1-2 107,191 (17.4) 129,336 (18.3) 2% 87,530 (17.4) 87,189 (17.3) 0% 
    3-5 256,541 (41.6) 289,615 (41.1) 1% 207,832 (41.3) 207,381 (41.2) 0% 
    ≥ 6 237,919 (38.6) 267,475 (37.9) 1% 196,246 (39.0) 197,396 (39.2) 0% 
Medication usel 
  Antiarrhythmic 8,265 (1.3) 13,318 (1.9) 4% 7,897 (1.6) 8,306 (1.6) 1% 
  Antipsychotic 15,803 (2.6) 24,798 (3.5) 6% 14,803 (2.9) 15,909 (3.2) 1% 
  Proton pump inhibitor 113,986 (18.5) 127,557 (18.1) 1% 94,018 (18.7) 94,081 (18.7) 0% 
  Antiemetic 3,353 (0.5) 4,417 (0.6) 1% 2,971 (0.6) 3,137 (0.6) 0% 
  Lithium 1,230 (0.2) 1,737 (0.2) 1% 1,071 (0.2) 1,079 (0.2) 0% 
  Antilipemic 221,688 (36.0) 272,129 (38.6) 5% 188,554 (37.4) 189,507 (37.6) 0% 
  Antihypertensive 378,579 (61.4) 441,513 (62.6) 2% 315,012 (62.6) 316,392 (62.8) 1% 
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  Potassium sparing  
  diuretic 7,394 (1.2) 7,828 (1.1) 1% 5,943 (1.2) 5,882 (1.2) 0% 
  H2RA 45,412 (7.4) 49,780 (7.1) 1% 37,562 (7.5) 38,034 (7.6) 0% 
  Prokinetic 12,338 (2.0) 14,799 (2.1) 1% 10,793 (2.1) 10,792 (2.1) 0% 
  QT-prolonging 79,216 (12.9) 96,628 (13.7) 3% 68,376 (13.6) 68,376 (13.6) 0% 
  Antidiabetic 86,160 (14.0) 107,168 (15.2) 3% 74,116 (14.7) 75,326 (15.0) 1% 
  Acetylsalicylic acid 45,102 (7.3) 50,932 (7.2) 0% 38,140 (7.6) 38,469 (7.6) 0% 
  Anticoagulantm 1,097 (0.2) 1,913 (0.3) 2% 1,053 (0.2) 1,116 (0.2) 0% 
  Antiplatelet 21,137 (3.4) 26,750 (3.8) 2% 18,705 (3.7) 18,835 (3.7) 0% 
  Tricyclic  
  antidepressant 16,779 (2.7) 18,043 (2.6) 1% 13,898 (2.8) 13,639 (2.7) 0% 
  Opioid 144 (0.0) 152 (0.0) 0% 115 (0.0) 121 (0.0) 0% 
  Antimalarian 4,165 (0.7) 3,976 (0.6) 1% 3,218 (0.6) 3,126 (0.6) 0% 
  Antiviral 70 (0.0) 78 (0.0) 0% 59 (0.0) 57 (0.0) 0% 
  Antineoplastic 18,251 (3.0) 19,862 (2.8) 1% 14,617 (2.9) 14,760 (2.9) 0% 
  Benzodiazepine 95,661 (15.5) 106,325 (15.1) 1% 78,922 (15.7) 79,561 (15.8) 0% 
  NSAIDn 96,993 (15.7) 102,468 (14.5) 3% 77,699 (15.4) 77,092 (15.3) 0% 
  Cholinesterase  
  inhibitor 0 (0.0) 0 (0.0) 0% - - - 
  Anticonvulsant 12,039 (2.0) 17,052 (2.4) 3% 10,861 (2.2) 11,419 (2.3) 1% 
  ACE/ARB 244,089 (39.6) 286,273 (40.6) 2% 203,598 (40.4) 204,220 (40.6) 0% 
  Beta-adrenergic  
  antagonist 143,479 (23.3) 175,820 (24.9) 4% 122,840 (24.4) 123,696 (24.6) 0% 
  Calcium channel  
  blocker 137,188 (22.3) 162,728 (23.1) 2% 115,643 (23.0) 116,434 (23.1) 0% 
  Non-potassium  
  sparing diuretic 140,191 (22.7) 164,702 (23.4) 1% 117,731 (23.4) 118,689 (23.6) 0% 
 31 
 
 
  Statin 206,154 (33.4) 253,885 (36.0) 5% 175,534 (34.9) 176,476 (35.0) 0% 
  Antiparkinson drug 7,655 (1.2) 11,610 (1.6) 3% 6,976 (1.4) 7,263 (1.4) 0% 
  Digoxin 16,465 (2.7) 27,748 (3.9) 7% 15,850 (3.1) 17,362 (3.4) 2% 
  Overactive bladder  
  medication 11,989 (1.9) 15,337 (2.2) 2% 10,306 (2.0) 10,385 (2.1) 0% 
  Warfarin 28,511 (4.6) 52,322 (7.4) 12% 27,911 (5.5) 31,117 (6.2) 3% 
  Inhaler  -    
  acetylcholine 26,454 (4.3) 26,784 (3.8) 3% 21,534 (4.3) 21,606 (4.3) 0% 
  Inhaler - corticosteroid 38,465 (6.2) 32,138 (4.6) 7% 28,792 (5.7) 27,560 (5.5) 1% 
  Inhaler  - beta-agonist 71,383 (11.6) 61,638 (8.7) 9% 54,089 (10.7) 52,530 (10.4) 1% 
  Smoking cessation aid 213 (0.0) 220 (0.0) 0% 162 (0.0) 164 (0.0) 0% 
Health care useo 
  GP/FP visits 588,000 (95.4) 671,789 (95.3) 1% 480,748 (95.5) 481,050 (95.5) 0% 
Specialist consultations 
  Nephrologist consults 23,354 (3.8) 31,104 (4.4) 3% 20,866 (4.1) 21,237 (4.2) 0% 
  Cardiologist consults 192,925 (31.3) 233,623 (33.1) 4% 163,132 (32.4) 164,185 (32.6) 0% 
Prior investigations and treatments 
  Carotid ultrasound 23,718 (3.8) 27,395 (3.9) 0% 19,805 (3.9) 19,657 (3.9) 0% 
  Cardiac catheterization 7,618 (1.2) 10,102 (1.4) 2% 6,875 (1.4) 7,053 (1.4) 0% 
  Coronary angiogram 8,845 (1.4) 11,493 (1.6) 2% 7,944 (1.6) 8,096 (1.6) 0% 
  Echocardiography 76,276 (12.4) 95,002 (13.5) 3% 65,733 (13.1) 66,452 (13.2) 0% 
  EEG 2,452 (0.4) 3,074 (0.4) 1% 2,098 (0.4) 2,099 (0.4) 0% 
  Holter monitoring 27,888 (4.5) 35,025 (5.0) 2% 23,889 (4.7) 24,311 (4.8) 0% 
  Cardiac stress test 59,803 (9.7) 68,956 (9.8) 0% 49,842 (9.9) 49,678 (9.9) 0% 
  Coronary  
  revascularization 4,282 (0.7) 5,866 (0.8) 2% 3,917 (0.8) 4,044 (0.8) 0% 
  ECG 270,574 (43.9) 319,725 (45.3) 3% 225,533 (44.8) 226,738 (45.0) 0% 
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  Colorectal cancer  
  screening 120,943 (19.6) 135,540 (19.2) 1% 96,970 (19.3) 96,028 (19.1) 0% 
  Cervical cancer  
  screening 50,974 (8.3) 52,085 (7.4) 3% 39,122 (7.8) 38,535 (7.7) 0% 
  PSA test 11,272 (1.8) 16,987 (2.4) 4% 10,216 (2.0) 10,024 (2.0) 0% 
  Mammography 62,602 (10.2) 62,137 (8.8) 5% 48,148 (9.6) 47,222 (9.4) 1% 
  Influenza vaccination 330,636 (53.6) 372,220 (52.8) 2% 269,517 (53.5) 269,306 (53.5) 0% 
  Bone mineral density  
  test 78,822 (12.8) 82,424 (11.7) 3% 61,728 (12.3) 60,823 (12.1) 1% 
  Hearing test 28,892 (4.7) 32,190 (4.6) 1% 23,566 (4.7) 23,393 (4.6) 0% 
  Cystoscopy 16,682 (2.7) 21,408 (3.0) 2% 14,405 (2.9) 14,577 (2.9) 0% 
  Transurethral   
  resection of the  
  prostate 
1,314 (0.2) 1,869 (0.3) 1% 1,169 (0.2) 1,211 (0.2) 0% 
  CT of the head 36,303 (5.9) 47,676 (6.8) 4% 31,556 (6.3) 32,637 (6.5) 1% 
  CT of other areas 53,665 (8.7) 63,780 (9.0) 1% 45,195 (9.0) 45,595 (9.1) 0% 
  Chest x-ray 25,312 (4.1) 22,786 (3.2) 5% 19,484 (3.9) 19,263 (3.8) 0% 
  Pulmonary function  
  test 50,909 (8.3) 51,816 (7.3) 3% 40,495 (8.0) 40,142 (8.0) 0% 
  At-home physician  
  service 16,262 (2.6) 19,799 (2.8) 1% 14,109 (2.8) 14,329 (2.8) 0% 
  Urinalysis 9,521 (1.5) 34,249 (4.9) 19% 9,520 (1.9) 9,786 (1.9) 0% 
  Sputum 483 (0.1) 399 (0.1) 1% 367 (0.1) 356 (0.1) 0% 
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Kidney functionp 
  Baseline SCr   
  concentration, median  
  (IQR), μmol/L 
78 (66-93) 79 (67-94) 4% 79 (67-93) 78 (66-93) 1% 
  eGFR, median (IQR),   
  mL/min/1.73 m2q 74 (61-86) 74 (61-86) 2% 74 (61-86) 74 (61-86) 1% 
  eGFR 
   ≥ 60 mL/min/1.73 m2 81,332 (13.2) 95,913 (13.6) 1% 66,755 (13.3) 66,942 (13.3) 0% 
   45-59 mL/min/1.73 m2 16,125 (2.6) 19,597 (2.8) 1% 13,793 (2.7) 13,534 (2.7) 0% 
   30-44 mL/min/1.73 m2 6,352 (1.0) 8,217 (1.2) 1% 5,630 (1.1) 5,637 (1.1) 0% 
   15-29 mL/min/1.73 m2 1,735 (0.3) 2,478 (0.4) 1% 1,581 (0.3) 1,661 (0.3) 0% 
   < 15 mL/min/1.73 m2 226 (0.0) 310 (0.0) 0% 217 (0.0) 202 (0.0) 0% 
  Urine dipstick proteinr 
   Negative (≤ 0.3 g/L) 612 (0.1) 803 (0.1) 0% 533 (0.1) 508 (0.1) 0% 
   0.3 g/L - 1.0 g/L 8,734 (1.4) 10,935 (1.6) 1% 7,362 (1.5) 7,372 (1.5) 0% 
   1.0 g/L - 3.0 g/L 6,985 (1.1) 8,933 (1.3) 1% 5,926 (1.2) 6,148 (1.2) 0% 
   ≥ 3.0 g/L 6,250 (1.0) 8,444 (1.2) 2% 5,517 (1.1) 5,711 (1.1) 0% 
Abbreviations: ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor blocker, CKD = chronic kidney disease, CKD-EPI = 
Chronic Kidney Disease Epidemiology Collaboration, CT = computed tomography, DVT/PE = deep vein thrombosis/pulmonary embolism,  
ECG = electrocardiography, EEG = electroencephalography, eGFR = estimated glomerular filtration rate, GP/FP = general practitioner/family 
practitioner, H2RA = histamine H2-receptor antagonist, IQR = interquartile range, LHIN = Local Health Integration Network, NSAID = non-
steroidal anti-inflammatory drug, PSA = prostate-specific antigen, SCr = serum creatinine, SD = standard deviation, TIA = transient ischemic 
attack 
aData are presented as the number (percentage) of patients, unless otherwise reported. 
bStandardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between 
groups divided by the pooled standard deviation; a value greater than 10% (0.1) is interpreted as a meaningful difference between the groups (71).  
cIncome was categorized into fifths of average neighborhood income on the index date. Income was not available for 2,160 (0.4%) macrolide 
antibiotic users and 2,468 (0.4%) non-macrolide antibiotic users in the unmatched cohort. Missing values in the unmatched cohort were  
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re-classified into income quintile 3 during matching. 
dRural residence was defined as a population < 10,000 people. Residential information was not available for 647 (0.1%) macrolide antibiotic users 
and 708 (0.1%) non-macrolide antibiotic users in the unmatched cohort. Missing values in the unmatched cohort were re-classified into the "No" 
category during matching. 
eLHIN refers to health authorities responsible for regional administration of public healthcare services in Ontario. LHIN was not available for 619 
(0.1%) macrolide antibiotic users and 684 (0.1%) non-macrolide antibiotic users in the unmatched cohort and 500 (0.1%) macrolide users and 480 
(0.1%) non-macrolide antibiotic users in the matched cohort. 
fPrescriber information was not available for 100,111 (16.2%) macrolide antibiotic users and 262,915 (37.3%) non-macrolide antibiotic users in 
the unmatched cohort and 100,093 (19.9%) macrolide antibiotic users and 95,973 (19.1%) non-macrolide antibiotic users in the matched cohort. 
gComorbid conditions in the five years preceding the index date were considered. 
hWe identified CKD using an algorithm of hospital diagnostic diagnosis codes validated for older adults in our region (83). The presence of codes 
in this algorithm is associated with a median eGFR of 38 mL/min/1.73 m2 (IQR 27 to 52 mL/min/1.73 m2), whereas an absence of codes is 
associated with a median eGFR of 69 mL/min/1.73 m2 (IQR 56 to 82 mL/min/1.73 m2).  
iCoronary artery disease included receipt of coronary artery bypass graft surgery and percutaneous coronary intervention. 
jMajor cancers included esophagus, lung, bowel, liver, pancreas, breast, male/female reproductive organs, as well as leukemias and lymphomas. 
kCharlson comorbidity index (84,85) was calculated using five years of hospitalization data. "No hospitalizations" received a score of 0. 
lBaseline medication use in the 120 days preceding the index date was considered. 
mExcludes warfarin. 
nExcludes acetylsalicylic acid. 
oChest x-ray, urinalysis and sputum were assessed in the seven days preceding the index date. All other health care use was assessed in the one 
year preceding the index date. 
pBaseline SCr measurements were taken in routine care a median of 131 days (IQR 59 to 227 days) and 126 days (IQR 57 to 224 days) prior to the 
index date for macrolide antibiotic users and non-macrolide antibiotic users, respectively, in the unmatched cohort and 129 days (IQR 59 to 225 
days) and 127 days (IQR 58 to 224 days) prior to the index date for macrolide antibiotic users and non-macrolide antibiotic users, respectively, in 
the matched cohort.  
qeGFR was calculated using the CKD-EPI equation (86): 141 × min([serum creatinine concentration in μmol/L/88.4]/ĸ, 1)α × max([serum 
creatinine concentration in μmol/L/88.4]/ĸ, 1)-1.209 × 0.993Age × 1.018 [if female] × 1.159 [if African-American]; ĸ = 0.7 if female and 0.9 if male; 
α = -0.329 if female and -0.411 if male; min = the minimum of serum creatinine concentration/ĸ or 1; max = the maximum of serum creatinine 
concentration/ĸ or 1. Information on race was not available in our data sources and all patients were assumed not to be of African-Canadian race; 
African-Canadians represented less than 5% of the population of Ontario in 2006 (87). 
rUrine dipstick protein measurements were available for 22,581 (3.7%) macrolide antibiotic users and 29,115 (4.1%) non-macrolide antibiotic 
users in the unmatched cohort and 19,338 (3.8%) macrolide antibiotic users and 19,739 (3.9%) non-macrolide antibiotic users in the matched 
cohort. 
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Table 3. 30-day risk for hospital encounter with ventricular arrhythmia and all-cause 
mortality in matched cohort of patients prescribed macrolide antibiotics compared to 
referent non-macrolide antibiotics 
 
Outcome 
Events, n (%) 
Relative Risk 
(95% CI) P value Macrolide 
(n = 503,612) 
Non-Macrolide 
(n = 503,612) 
Ventricular 
arrhythmiaa 134 (0.03) 126 (0.03) 1.06 (0.83-1.36) 0.62 
All-cause 
mortality 3,144 (0.62) 3,833 (0.76) 0.82 (0.78-0.86) < 0.0001 
Abbreviations: CI = confidence interval 
aBased on hospital presentation (emergency room or hospitalization) assessed by 
hospital diagnosis codes. This method of assessment underestimated the true number of 
events as ventricular arrhythmias frequently go undetected in routine healthcare 
(because they often occur outside hospital settings, in unmonitored patients in hospital 
or in a setting of multi-organ medical illness where recorded codes describe other 
illnesses besides the ventricular arrhythmia). 
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Abbreviations: CAD = coronary artery disease, CHF = congestive heart failure, CKD = chronic kidney disease 
Data marker size is proportional to the inverse of the source variance. 
aBased on hospital presentation (emergency room or hospitalization) assessed by hospital diagnosis codes. This method of assessment 
underestimated the true number of events as ventricular arrhythmias frequently go undetected in routine healthcare (because they often 
occur outside hospital settings, in unmonitored patients in hospital or in a setting of multi-organ medical illness where recorded codes 
describe other illnesses besides the ventricular arrhythmia).  
Figure 2. The association between macrolide antibiotic prescription (azithromycin, clarithromycin or erythromycin) and 30-day 
hospital encounter with ventricular arrhythmiaa examined in subgroups defined by CKD, CHF, CAD and QT-prolonging drug use 
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Abbreviations: CAD = coronary artery disease, CHF = congestive heart failure, CKD = chronic kidney disease 
Data marker size is proportional to the inverse of the source variance. 
 
Figure 3. The association between macrolide antibiotic prescription (azithromycin, clarithromycin or erythromycin) and 30-day  
all-cause mortality examined in subgroups defined by CKD, CHF, CAD and QT-prolonging drug use 
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Chapter 6  
6 Discussion 
In this population-based cohort study, we observed that new use of a macrolide antibiotic 
compared to non-macrolide antibiotics was associated with a similar 30-day risk of 
ventricular arrhythmia (0.03% vs. 0.03%) and a slightly lower risk of all-cause mortality 
(0.62% vs. 0.76%).  
 
6.1 Summary and interpretation of study results 
The studies included in our literature review show inconsistent findings. Although a 
plausible explanation for these observed differences may be variation in the average age, 
sex and baseline comorbidity of the studied populations, some publications warrant 
further attention.  
Of particular interest is the comparison of our findings with those of Ray et al. who 
observed a higher 5-day risk of cardiovascular death (HR 2.49, 95% CI 1.38-4.50) and 
death from any cause (HR 2.02, 95% CI 1.24-3.30) among patients taking azithromycin 
compared with those taking amoxicillin (8). Although the authors matched azithromycin 
use to antibiotic non-use, no matching was done for those prescribed amoxicillin. 
Compared with the azithromycin group, patients receiving amoxicillin seemed healthier 
overall, with lower percentages of baseline medication use (with the exception of digoxin 
and insulin), lower prevalence of comorbidities and fewer hospitalizations and 
emergency department visits. Accordingly, fewer deaths could have occurred among 
those receiving amoxicillin if they were less prone to events than the macrolide antibiotic 
group.  
In this same study, the authors reported the greatest risk of cardiovascular death in 
patients with the highest baseline risk of cardiovascular disease. Additionally, Schembri 
et al. reported an increased risk of cardiovascular events with prolonged courses of 
clarithromycin (> 7 days), especially in patients with pre-existing coronary artery disease 
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(18). For these reasons, we explored congestive heart failure and coronary artery disease 
as subgroups in our study. We found that these variables did not significantly alter the 
association between macrolide antibiotic use and our outcomes. Nonetheless, these 
findings should be interpreted with caution and physicians should always consider a 
patient’s baseline risk for adverse events before prescribing macrolides or other 
antibiotics. Patients at particular risk include those with existing QT interval 
prolongation, a history of torsades de pointes, hypokalemia, hypomagnesemia, significant 
bradycardia, bradyarrhythmias or use of certain antiarrhythmic drugs (88–90). To 
minimize risk, others advocate for ECG to monitor the QT interval before and after 
initiating therapy (91).  
A plausible explanation for the observed reduction in 30-day all-cause mortality with 
macrolide antibiotic use may be their immunomodulatory effects (92). These effects are 
believed to be mediated by several properties of macrolide antibiotics that have been 
observed including decreases in pro-inflammatory cytokines (TNF-α, IL-1, IL-6, IL-8 
and IFN-γ), increases in anti-inflammatory cytokines and decreases in neutrophil 
chemotaxis, leukocyte adhesion, and oxidative metabolism (93). However, because the 
absolute magnitude of this effect was small, this finding should be interpreted with 
caution. 
 
6.2 Study strengths and limitations 
Our study has several strengths. The use of Ontario’s healthcare databases with data on 
universal prescription drug coverage in older adults provided us with a large 
representative sample of patients who received the study antibiotics in routine care. This 
allowed us to estimate the risks of uncommon but serious adverse events with good 
precision and external validity. We assessed clinically important adverse events (hospital 
encounter with ventricular arrhythmia and death), rather than relying on surrogate 
outcomes such as a prolonged QT interval on an ECG, making these findings of 
particular interest to clinicians and regulatory agencies. We used the non-macrolide 
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antibiotics amoxicillin, cefuroxime and levofloxacin as a referent group to reduce the 
influence of confounding by indication.  
Experimental studies provide the strongest evidence for whether or not an exposure has 
an effect on the risk of a disease (94). However, clinical trials are costly and the relatively 
small number of patients enrolled in the trials makes the estimation of risk for relatively 
rare adverse drug events difficult (95). Large observational studies can complement the 
findings of clinical trials by enabling the investigation of uncommon but important 
adverse drug events with adequate statistical power. Moreover, such observational studies 
can include vulnerable groups of patients who may be excluded from clinical trials and 
better reflect what occurs in routine clinical settings where treatments and monitoring are 
less regulated than in clinical trials (96,97) 
Our study has some limitations. Prospective data collection with independent outcome 
adjudication would be a preferred methodology to assess risk. In this study, we analyzed 
retrospective data using administrative diagnosis codes assigned from physician records, 
and cardiac rhythm tracings were not available in our data sources. The diagnosis codes 
we used for a hospital encounter with ventricular arrhythmia have a good PPV but limited 
sensitivity. However, we have no reason to suspect any systematic difference in 
diagnostic recording by antibiotic type, suggesting that our relative measures of risk are 
robust. As with all observational studies, residual confounding can never be eliminated; 
however, we used a statistical technique to ensure our comparison groups were similar on 
106 measured baseline characteristics. Our findings might not generalize well to other 
regions if Ontario physicians deliberately avoided prescribing macrolide antibiotics to 
patients at highest risk of ventricular arrhythmia (such as those with baseline QT 
prolongation), or discontinued macrolide antibiotics when the QT interval was prolonged 
in a follow-up ECG. However, our impression is that Ontario physicians rarely take 
ventricular arrhythmia risk into account when deciding to prescribe a macrolide. 
Although shorter follow-up periods were used in prior studies (8–10,12,17,18,37), we 
consider the 30-day follow-up used in our study to be clinically relevant. We did, 
however, repeat our analyses within 14 days of macrolide antibiotic prescription and 
found similar results. 
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6.3 Study implications 
This study was prompted by Health Canada and U.S. FDA warnings about a higher risk 
of QT interval prolongation and subsequent ventricular arrhythmia among patients taking 
azithromycin (5,6). Though caution should be exercised when prescribing macrolide 
antibiotics to high-risk patients where drug clearance or electrical activity of the heart is 
impaired and outcomes less predictable, our study findings and examination of the 
current literature suggest that the risk of ventricular arrhythmia and death from macrolide 
antibiotic use may be overstated. A careful re-examination and updating of drug 
prescribing references (44,57–59) and warnings from regulatory agencies appears 
warranted. The findings from this study are reassuring for health care providers who 
prescribe macrolide antibiotics to a wide range of patients in routine care. 
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Appendices 
Appendix A. Modified Downs and Black checklist for the assessment of the 
methodological quality of both randomized and non-randomized studies (36) 
 
Item Criteria Possible Answers 
Reporting 
1 Is the hypothesis/aim/objective of the study clearly described? 
Yes = 1 
No = 0 
2 
Are the main outcomes to be measured clearly described in 
the Introduction or Methods section? If the main outcomes 
are first mentioned in the Results section, the question 
should be answered no. 
Yes = 1 
No = 0 
3 
Are the characteristics of the patients included in the study 
clearly described? In cohort studies and trials, inclusion 
and/or exclusion criteria should be given. In case-control 
studies, a case-definition and the source for controls should 
be given. 
Yes = 1 
No = 0 
4 
Are the interventions of interest clearly described? 
Treatments and placebo (where relevant) that are to be 
compared should be clearly described. 
Yes = 1 
No = 0 
5 
Are the distributions of principal confounders in each 
group of subjects to be compared clearly described? A list 
of principal confounders is provided. 
Yes = 2 
Partially = 1 
No = 0 
6 
Are the main findings of the study clearly described? 
Simple outcome data (including denominators and 
numerators) should be reported for all major findings so 
that the reader can check the major analyses and 
conclusions. (This question does not cover statistical tests 
which are considered below). 
Yes = 1 
No = 0 
7 
Does the study provide estimates of the random variability 
in the data for the main outcomes? In non-normally 
distributed data the interquartile range of results should be 
reported. In normally distributed data the standard error, 
standard deviation or confidence intervals should be 
reported. If the distribution of the data is not described, it 
must be assumed that the estimates used were appropriate 
and the question should be answered yes. 
Yes = 1 
No = 0 
8 
Have all important adverse events that may be a 
consequence of the intervention been reported? This 
should be answered yes if the study demonstrates that there 
was a comprehensive attempt to measure adverse events. 
(A list of possible adverse events is provided). 
Yes = 1 
No = 0 
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9 
Have the characteristics of patients lost to follow-up been 
described? This should be answered yes where there were 
no losses to follow-up or where losses to follow-up were so 
small that findings would be unaffected by their inclusion. 
This should be answered no where a study does not report 
the number of patients lost to follow-up. 
Yes = 1 
No = 0 
10 
Have actual probability values been reported (e.g. 0.035 
rather than <0.05) for the main outcomes except where the 
probability value is less than 0.001? 
Yes = 1 
No = 0 
External validity 
11 
Were the subjects asked to participate in the study 
representative of the entire population from which they 
were recruited? The study must identify the source 
population for patients and describe how the patients were 
selected. Patients would be representative if they 
comprised the entire source population, an unselected 
sample of consecutive patients, or a random sample. 
Random sampling is only feasible where a list of all 
members of the relevant population exists. Where a study 
does not report the proportion of the source population 
from which the patients are derived, the question should be 
answered as unable to determine. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
12 
Were those subjects who were prepared to participate 
representative of the entire population from which they 
were recruited? The proportion of those asked who agreed 
should be stated. Validation that the sample was 
representative would include demonstrating that the 
distribution of the main confounding factors was the same 
in the study sample and the source population. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
13 
Were the staff, places, and facilities where the patients 
were treated, representative of the treatment the majority 
of patients receive? For the question to be answered yes 
the study should demonstrate that the intervention was 
representative of that in use in the source population. The 
question should be answered no if, for example, the 
intervention was undertaken in a specialist centre 
unrepresentative of the hospitals most of the source 
population would attend. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
Internal validity - bias 
14 
Was an attempt made to blind study subjects to the 
intervention they have received? For studies where the 
patients would have no way of knowing which intervention 
they received, this should be answered yes. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
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15 
Was an attempt made to blind those measuring the main 
outcomes of the intervention? 
Yes = 1 
No = 0 
Unable to 
determine = 0 
16 
If any of the results of the study were based on “data 
dredging”, was this made clear? Any analyses that had not 
been planned at the outset of the study should be clearly 
indicated. If no retrospective unplanned subgroup analyses 
were reported, then answer yes. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
17 
In trials and cohort studies, do the analyses adjust for 
different lengths of follow-up of patients, or in case-control 
studies, is the time period between the intervention and 
outcome the same for cases and controls? Where follow-
up was the same for all study patients the answer should be 
yes. If different lengths of follow-up were adjusted for by, 
for example, survival analysis the answer should be yes. 
Studies where differences in follow-up are ignored should 
be answered no. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
18 
Were the statistical tests used to assess the main outcomes 
appropriate? The statistical techniques used must be 
appropriate to the data. For example nonparametric 
methods should be used for small sample sizes. Where 
little statistical analysis has been undertaken but where 
there is no evidence of bias, the question should be 
answered yes. If the distribution of the data (normal or not) 
is not described it must be assumed that the estimates used 
were appropriate and the question should be answered yes. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
19 
Was compliance with the intervention/s reliable? Where 
there was non-compliance with the allocated treatment or 
where there was contamination of one group, the question 
should be answered no. For studies where the effect of any 
misclassification was likely to bias any association to the 
null, the question should be answered yes. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
20 
Were the main outcome measures used accurate (valid and 
reliable)? For studies where the outcome measures are 
clearly described, the question should be answered yes. For 
studies which refer to other work or that demonstrates the 
outcome measures are accurate, the question should be 
answered as yes. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
Internal validity - confounding (selection bias) 
21 
Were the patients in different intervention groups (trials 
and cohort studies) or were the cases and controls (case-
control studies) recruited from the same population? For 
example, patients for all comparison groups should be 
selected from the same hospital. The question should be 
answered unable to determine for cohort and case-control 
Yes = 1 
No = 0 
Unable to 
determine = 0 
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studies where there is no information concerning the 
source of patients included in the study. 
22 
Were study subjects in different intervention groups (trials 
and cohort studies) or were the cases and controls (case-
control studies) recruited over the same period of time? 
For a study which does not specify the time period over 
which patients were recruited, the question should be 
answered as unable to determine. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
23 
Were study subjects randomized to intervention groups? 
Studies which state that subjects were randomized should 
be answered yes except where method of randomization 
would not ensure random allocation. For example alternate 
allocation would score no because it is predictable. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
24 
Was the randomized intervention assignment concealed 
from both patients and health care staff until recruitment 
was complete and irrevocable? All non-randomized 
studies should be answered no. If assignment was 
concealed from patients but not from staff, it should be 
answered no. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
25 
Was there adequate adjustment for confounding in the 
analyses from which the main findings were drawn? This 
question should be answered no for trials if: the main 
conclusions of the study were based on analyses of 
treatment rather than intention to treat; the distribution of 
known confounders in the different treatment groups was 
not described; or the distribution of known confounders 
differed between the treatment groups but was not taken 
into account in the analyses. In non-randomized studies if 
the effect of the main confounders was not investigated or 
confounding was demonstrated but no adjustment was 
made in the final analyses the question should be answered 
as no. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
26 
Were losses of patients to follow-up taken into account? If 
the numbers of patients lost to follow-up are not reported, 
the question should be answered as unable to determine. If 
the proportion lost to follow-up was too small to affect the 
main findings, the question should be answered yes. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
Power 
27a 
Did the study have sufficient power to detect a clinically 
important effect where the probability value for a 
difference being due to chance is less than 5%? Sample 
sizes have been calculated to detect a difference of x% and 
y%. 
Yes = 1 
No = 0 
Unable to 
determine = 0 
aItem has been modified. 
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Appendix B. Checklist of recommendations for reporting of observational studies using 
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
guidelines (40) 
 
  Item No Recommendation Reported 
Title and 
abstract 1 
(a) Indicate the study's design with 
a commonly used term in the title 
or the abstract 
Abstract 
(b) Provide in the abstract an 
informative and balanced 
summary of what was done and 
what was found 
Abstract 
Introduction 
  Background/   
  rationale 2 
Explain the scientific background 
and rationale for the investigation 
being reported 
Chapters 1, 2 & 3 
  Objectives 3 State specific objectives, including any prespecified hypotheses Chapter 3 
Methods 
  Study design 4 Present key elements of study design early in the paper Chapter 4 
  Setting 5 
Describe the setting, locations, and 
relevant dates, including periods of 
recruitment, exposure, follow-up, 
and data collection 
Chapter 4 
  Participants 6 
(a) Give the eligibility criteria, and 
the sources and methods of 
selection of participants. Describe 
methods of follow-up 
Chapter 4, Figure 1 
(b) For matched studies, give 
matching criteria and number of 
exposed and unexposed 
Chapter 4, Figure 1  
  Variables 7 
Clearly define all outcomes, 
exposures, predictors, potential 
confounders, and effect modifiers. 
Give diagnostic criteria, if 
applicable 
Chapter 4, 
Appendices C, D, 
E, F & G  
  Data sources/  
  measurement 8 
For each variable of interest, give 
sources of data and details of 
methods of assessment 
(measurement). Describe 
comparability of assessment 
Chapter 4, 
Appendices C & D 
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methods if there is more than one 
group 
  Bias 9 Describe any efforts to address potential sources of bias Chapters 4 & 6 
  Study size 10 Explain how the study size was arrived at 
Chapter 4; based on 
availability of the 
data 
  Quantitative  
  variables 11 
Explain how quantitative variables 
were handled in the analyses. If 
applicable, describe which 
groupings were chosen and why 
Chapter 4 
  Statistical  
  methods 12 
(a) Describe all statistical methods, 
including those used to control for 
confounding 
Chapter 4 
(b) Describe any methods used to 
examine subgroups and 
interactions 
Chapter 4 
(c) Explain how missing data were 
addressed Chapter 4 
(d) If applicable, explain how loss 
to follow-up was addressed Not applicable 
(e) Describe any sensitivity 
analyses Chapter 4 
Results 
  Participants 13 
(a) Report numbers of individuals 
at each stage of study-e.g. numbers 
potentially eligible, examined for 
eligibility, confirmed eligible, 
included in the study, completing 
follow-up, and analyzed 
Chapter 5, Figure 1 
(b) Give reasons for non-
participation at each stage Chapter 5, Figure 1 
(c) Consider use of a flow diagram Figure 1 
  Descriptive data 14 
(a) Give characteristics of study 
participants (e.g. demographic, 
clinical, social) and information on 
exposures and potential 
confounders 
Chapter 5, Table 2, 
Appendix G 
(b) Indicate number of participants 
with missing data for each variable 
of interest 
Chapter 5, Table 2, 
Appendix I 
(c) Summarize follow-up time 
(e.g. average and total amount) Chapter 5 
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  Outcome data 15 Report numbers of outcome events or summary measures over time Chapter 5, Table 3 
  Main results 16 
(a) Give unadjusted estimates and, 
if applicable, confounder-adjusted 
estimates and their precision (e.g. 
95% confidence interval). Make 
clear which confounders were 
adjusted for and why they were 
included 
Chapter 5, Table 2, 
Appendix G 
(b) Report category boundaries 
when continuous variables were 
categorized 
Not applicable 
(c) If relevant, consider translating 
estimates of relative risk into 
absolute risk for a meaningful time 
period 
Not applicable 
  Other analyses 17 
Report other analyses done-e.g. 
analyses of subgroups and 
interactions, and sensitivity 
analyses 
Chapter 5, Figures 1 
and 2, Appendices I 
& J 
Discussion 
  Key results 18 Summarize key results with reference to study objectives Chapter 6 
  Limitations 19 
Discuss limitations of the study, 
taking into account sources of 
potential bias or imprecision. 
Discuss both direction and 
magnitude of any potential bias 
Chapter 6 
  Interpretation 20 
Give a cautious overall 
interpretation of results 
considering objectives, limitations, 
multiplicity of analyses, results 
from similar studies, and other 
relevant evidence 
Chapter 6 
  Generalizability 21 
Discuss the generalizability 
(external validity) of the study 
results 
Chapter 6 
Other information 
  Funding 22 
Give the source of funding and the 
role of the funders for the present 
study and, if applicable, for the 
original study on which the present 
article is based 
Acknowledgements 
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Appendix C. Coding definitions for demographics and comorbid conditions 
 
Variable Database Codes 
Demographics 
Age RPDB   
Sex RPDB   
Socioeconomic status 
(neighbourhood income 
quintiles) 
Statistics 
Canada 
  
Location of residence - 
Rural status 
Statistics 
Canada 
  
Long-term care ODB LTC 
Prescribing physician / 
LHINa 
RPDB LHIN 
Comorbidities 
Dementia CIHI-DAD 
 
 
 
OHIP 
OMHRS 
ICD-9: 2900, 2901, 2903, 2904, 2908, 
2909, 2948, 2949, 3310-3312, 2941, 797 
ICD-10: F00-F03, F051, F065, F066, 
F068, F069, F09, G30, G31, R54 
OHIP dx: 290, 331, 797 
DSM-IV: 29040-29043, 29120, 29282, 
29410, 29411, 29480, 78090 
Schizophrenia or other 
psychotic disorders 
CIHI-DAD  
 
 
 
 
 
 
 
 
OHIP  
 
OMHRS 
ICD-9: 2950-2959, 2970-2973, 2978-2981, 
2983, 2984, 2988, 2989 
ICD-10: F060, F062, F105, F107, F115, 
F117, F125, F127, F135, F137, F145, 
F147, F155, F157, F165, F167, F175, 
F177, F185, F187, F195, F197, F200-
F206, F208, F209, F220, F228-F233, 
F238, F239, F24, F250-F252, F258, F259, 
F28, F29 
OHIP dx: 291, 292, 295, 297, 298 
OHIP fee: Q021 
DSM-IV: 29130, 29150, 29211, 29212, 
29381, 29382, 29510, 29520, 29530, 
29540, 29560, 29570, 29590, 29710, 
29730, 29880, 29890 
Bipolar disorder CIHI-DAD  
 
OHIP  
 
OMHRS 
ICD-9: 2960, 2961, 2964-2968 
ICD-10: F300-F302, F308-F319 
OHIP dx: 296 
OHIP fee: Q020 
DSM-IV: 29600-29606, 29640-29646, 
29650-29656, 29660-29666, 29670, 29680, 
29689 
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Unipolar depression 
and/or anxiety disorder 
CIHI-DAD  
 
 
 
 
OHIP  
OMHRS 
ICD-9: 2962, 2963, 3000, 3002-3004, 
3091, 311 
ICD-10: F063, F064, F320-F323, F328-
F334, F338, F339, F341, F400-F402, 
F408-F413, F418-F422, F428-F431 
OHIP dx: 311 
DSM-IV: 29189, 29284, 29289, 29383, 
29384, 29620-29626, 29630-29636, 
30000-30002, 30021-30023, 30029, 30030, 
30040, 30113 
Haemorrhagic stroke  CIHI-DAD ICD-9: 430, 431 
ICD-10: I600-I607, I609, I61 
Ischemic stroke  CIHI-DAD ICD-9: 434, 436 
ICD-10: H341, I630-I635, I638, I639 
Transient ischemic 
attack 
CIHI-DAD ICD-9: 4358, 4359 
ICD-10: G45 
Chronic kidney disease  
CORR  
 
CIHI-DAD  
 
 
 
OHIP 
 
 
 
CIHI-DAD  
 
OHIP 
 
 
 
CIHI-DAD 
 
OHIP 
 
 
 
 
 
CIHI-DAD 
 
 
 
OHIP 
Transplant 
Treatment code: 171, 181 
Transplanted organ: 10-12, 18, 19 
ICD-9: V420, 99681 
ICD-10: N165, T861, Z940 
CCP: 6743, 675 
CCI: 1PC85 
OHIP fee: E762, E769, E771, G347, G348, 
G408, G409, G412, S434, S435, Z631  
 
Peritoneal dialysis  
CCP: 6698 
CCI: 1PZ21HPD4 
OHIP fee: G330-G333, G861, G864, 
H540, H740 
 
Hemodialysis 
CCP: 5195  
CCI: 1PZ21HQBR, 1PZ21HQBS 
OHIP fee: G082, G083, G085, G090-
G096, G294, G295, G323, G325, G326, 
G333, G860, G862, G863, G865, G866, 
H540, H740, R849 
 
Chronic kidney disease 
ICD-9: 2504, 4030, 4031, 4039-4041, 
4049, 585, 586, 5888, 5889 
ICD-10: E102, E112, E132, E142, I12, I13, 
N08, N18, N19 
OHIP dx: 403, 585 
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Chronic liver disease CIHI-DAD  
 
 
 
 
 
 
OHIP  
ICD-9: 070, 2750, 2751, 4561, 4562, 571, 
5722-5724, 5728, 573, 7824, 7891, 7895, 
V026   
ICD-10: B16-B19, B942, E830, E831, I85, 
K70, K713-K715, K717, K721, K729, 
K73, K74, K753, K754, K758, K759, K76, 
K77, R160, R162, R17, R18, Z225 
OHIP dx: 070, 571, 573  
OHIP fee: Z551, Z554 
Congestive heart failure CIHI-DAD  
 
 
 
 
OHIP  
ICD-9: 425, 428, 514, 5184  
ICD-10: I255, I500, I501, I509, J81 
CCP: 4961-4964 
CCI: 1HP53, 1HP55, 1HZ53GRFR, 
1HZ53LAFR, 1HZ53SYFR 
OHIP dx: 428 
OHIP fee: R701, R702, Z429  
Coronary artery disease 
(minus angina) 
CIHI-DAD  
 
 
 
 
 
OHIP  
ICD-9: 410, 412, 414, 4292, 4295-4297 
ICD-10: I21-I25, R931, T822, Z955, Z958, 
Z959 
CCP: 4801-4805, 481-483 
CCI: 1IJ26, 1IJ27, 1IJ50, 1IJ54, 1IJ57, 
1IJ76 
OHIP dx: 410, 412 
OHIP fee: E646, E651, E652, E654, E655, 
G262, G298, R741-R743, Z434, Z448 
Angina CIHI-DAD  
 
OHIP  
ICD-9: 413 
ICD-10: I20 
OHIP dx: 413 
Peripheral vascular 
disease 
CIHI-DAD  
 
 
 
 
 
 
OHIP  
ICD-9: 4402, 4408, 4409, 4439, 444, 5571 
ICD-10: I700, I702, I708, I709, I731, I738, 
I739, K551 
CCP: 5014, 5016, 5018, 5028, 5038, 5125, 
5129  
CCI: 1KA50, 1KA76, 1KE76, 1KG26, 
1KG50, 1KG57, 1KG76MI, 1KG87 
OHIP fee: E626, E649, E672, R780, R783-
R787, R791, R794, R797, R804, R809, 
R813-R815, R855, R856, R867, R875, 
R936, R937, R860, R861, R933, R934 
Parkinson’s disease CIHI-DAD  
 
OHIP  
ICD-9: 332 
ICD-10: F023, G20 
OHIP dx: 332 
Chronic lung disease CIHI-DAD  
 
 
 
ICD-9: 4168, 4169, 491-496, 500-505, 
5064, 5069, 5081, 515-517, 5185, 5188, 
5198, 5199 
ICD-10: I272, I278, I279, J40-J45, J47, 
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OHIP  
J60-J68, J701, J703, J704, J708, J709, J82, 
J84, J92, J941, J949, J953, J961, J969, 
J984, J988, J989, J99 
OHIP dx: 491-494, 496, 501, 502, 515, 
518, 519 
OHIP fee: J889, J689 
Atrial fibrillation/flutter CIHI-DAD  ICD-9: 4273 
ICD-10: I48 
Cancer CIHI-DAD  
 
 
 
 
 
 
OHIP  
ICD-9: 150, 154, 155, 157, 162, 174, 175, 
185, 203-208, 2303, 2304, 2307, 2312, 
2330, 2334 
ICD-10: C15, C18-C20, C22, C25, C34, 
C50, C56, C61, C82, C83, C85, C91-C95, 
D00, D010-D012, D022, D05, D075, 971, 
980, 982, 984-991, 993 
OHIP dx: 203-208, 150, 154, 155, 157, 
162, 174, 175, 183, 185 
Alcoholism CIHI-DAD  ICD-9: 303, 3050 
ICD-10: E244, E512, F10, G312, G621, 
G721, I426, K292, K70, K860, T510, X45, 
X65, Y15, Y573, Z502, Z714, Z721  
Seizure CIHI-DAD  ICD-9: 345, 7803 
ICD-10: G40, G41, R560, R568 
Acute kidney injury  CIHI-DAD  ICD-9: 584 
ICD-10: N17 
Acute myocardial 
infarction  
CIHI-DAD  ICD-9: 410 
ICD-10: I21, I22 
Pacemaker  CIHI-DAD  
 
 
 
 
 
 
 
OHIP 
CCP: 0345-0349, 4971-4973, 4987 
CCI: 1HD53GRJA, 1HD54GRJA, 1HD55, 
1HZ09, 1HZ37, 1HZ53GRFR, 
1HZ53GRNK, 1HZ53GRNL, 
1HZ53GRNM, 1HZ53GRNN, 
1HZ53LAFR, 1HZ53SYFR, 1HZ54LANJ, 
1HZ55, 2HZ07NK, 2HZ07NL, 
2HZ07NM, 2HZ24 
OHIP fee: E628, G115, G176, G177, 
G303, R752, Z412, Z428, Z433-Z435, 
Z444-Z446  
Hyperkalemia CIHI-DAD  ICD-9: 2767 
ICD-10: E875 
Hypotension  CIHI-DAD  ICD-9: 458 
ICD-10: I95 
Prostatic hyperplasia  CIHI-DAD  
 
OHIP 
ICD-9: 600 
ICD-10: N40 
OHIP dx: 600 
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Prostatitis  CIHI-DAD  
 
OHIP 
ICD-9: 6010-6012 
ICD-10: N410-N412 
OHIP dx: 601 
Acute urinary retention CIHI-DAD  ICD-9: 7882 
ICD-10: R33 
Deep vein 
thrombosis/Pulmonary 
embolism  
CIHI-DAD  ICD-9: 4151, 4511, 4512, 514 
ICD-10: I26, I743, I801-I803 
Health care use 
GP/FP visits IPDB, OHIP Mainspecialty = GP/FP 
Specialist consultations 
Nephrologist consults IPDB 
OHIP 
Mainspecialty = NEPHROLOGY 
OHIP fee: A135, A161, A163-A166, 
A168, C101, C132, C135, C137, C138, 
E083, G323, G860 
   Dialysisb OHIP OHIP fee: G323, G325, G326, G330-
G332, G860-G866, R849 
Cardiologist consults IPDB, OHIP Mainspecialty = CARDIOLOGY 
Prior investigations and treatments 
Carotid ultrasound CIHI-DAD 
 
OHIP 
CCP: 0281 
CCI: 3JE30 
OHIP fee: J190, J191, J201, J501, J189, 
J489-J492 
Cardiac catheterization CIHI-DAD 
 
 
 
 
OHIP 
CCP: 4995-4997 
CCI: 2HZ24GPKJ, 2HZ24GPKL, 
2HZ24GPKM, 2HZ24GPXJ, 
2HZ28GPPL, 2HZ71GP,  3HZ30GP, 
3IJ30GP 
OHIP fee: G296, G297, G299-G301, 
G304-G306 
Coronary angiogram CIHI-DAD 
 
OHIP 
CCP: 4892-4898, 4996, 4997 
CCI: 3IP10 
OHIP fee: G297, Z442 
Echocardiography CIHI-DAD 
 
OHIP 
CCP: 0282  
CCI: 3IP30 
OHIP fee: G560-G562, G566-G568, G570-
G572, G574-G581 
Electroencephalography OHIP OHIP fee: G414-G418, G540, G542, 
G544-G546, G554, G555 
Holter monitoring CIHI-DAD 
OHIP 
CCI: 2HZ24JAKH 
OHIP fee: G650-G661, G682-G690, G692, 
G693 
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Cardiac stress test CIHI-DAD 
 
OHIP 
CCP: 0341-0344 
CCI: 2HZ08, 3IP70 
OHIP fee: G111, G112, G174, G315, 
G319, J604, J606-J609, J611-J613, J667, 
J804, J807-J809, J811-J813, J666, J866, 
J867 
Coronary 
revascularization 
CIHI-DAD 
 
 
OHIP 
CCP: 480-483 
CCI: 1IJ26, IIJ27, 1IJ50, 1IJ57, 1IJ76, 
1IJ54GQAZ, 1IJ57GQ 
OHIP fee: E646, E651, E652, E654, G262, 
G298, R741-R743, Z434 
Electrocardiography CIHI-DAD 
OHIP 
CCI: 2HZ24JAKE 
OHIP fee: G310, G313 
Colorectal cancer 
screening 
OHIP OHIP fee: G004, L179, L181, Q043, 
Q152, X112, X113, Z535, Z536, Z555, 
Z580 
Cervical cancer 
screening 
OHIP OHIP fee: E430, G365, G394, L713, L812 
Prostate-specific antigen 
test 
OHIP OHIP fee: L354, L358 
Mammography OHIP OHIP fee: X172, X178, X184, X185, X201 
Influenza vaccination OHIP OHIP fee: G590, G591 
Bone mineral density 
test 
OHIP OHIP fee: J654, J688, J854, J888, X149, 
X152, X153, X155, Y654, Y688, Y854, 
Y888 
Hearing test OHIP OHIP fee: G153, G154, G440-G443, 
G448, G450-G452, G525, G526, G529, 
G530, G533, G815, G816 
Cystoscopy OHIP OHIP fee: Z606, Z607, Z628, Z632-Z634 
Transurethral resection 
of the prostate 
CIHI-DAD 
 
 
 
 
OHIP 
CCP: 721 
CCI: 1QT59BAAD, 1QT59BAAG, 
1QT59BAAW, 1QT59BAAZ, 
1QT59BACG, 1QT59BAGX, 1QT87BA, 
1QT87BAAG, 1QT87BAAK 
OHIP fee: S655 
Computed tomography 
of head 
OHIP OHIP fee: X188, X400-X402, X405, X408 
Computed tomography 
of other areas 
OHIP OHIP fee: X124-X128, X231-X233, X403, 
X404, X406, X407, X409, X410, X412, 
X413, X415, X416  
Chest x-ray OHIP OHIP fee: X090-X092, X195 
Pulmonary function test OHIP OHIP fee: E450, E451, J301, J303-J311, 
J313, J315-J320, J322-J324, J327, J328, 
J330-J335, J340, J341 
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At-home physician 
services 
OHIP OHIP fee: A901, B960-B964, B966, B990, 
B992-B994, B996-B998 
Urinalysis OHIP OHIP fee: L253-L255, L633, L634, L641, 
G009, G010 
Sputum OHIP OHIP fee: L629, L716, L815 
  
Abbreviations: CCI = Canadian Classification of Health Interventions (available after 
2002), CCP = Canadian Classification of Diagnostic, Therapeutic and Surgical 
Procedures (before 2002), CIHI-DAD = Canadian Institute for Health Information 
Discharge Abstract Database, CORR = Canadian Organ Replacement Register, DSM-IV 
= Diagnostic and Statistical Manual of Mental Disorders, 4th edition, GP/FP = general 
practitioner/family practitioner, ICD-9 = International Classification of Diseases, Ninth 
Revision, ICD-10 = International Classification of Diseases, Tenth Revision, IPDB = 
Institute for Clinical Evaluative Sciences (ICES) Physician Database, LHIN = Local 
Health Integration Network, ODB = Ontario Drug Benefit, OHIP = Ontario Health 
Insurance Plan, OMHRS = Ontario Mental Health Reporting System,  RPDB = 
Registered Persons Database of Ontario 
aLHIN refers to health authorities responsible for regional administration of public 
healthcare services in Ontario. 
bOnly includes dialysis visits with nephrologist present. 
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Appendix D. Coding definitions for hospital encounter with ventricular arrhythmia and 
all-cause mortality 
 
Outcome Database Codes 
Ventricular arrhythmia CIHI-DAD, NACRS ICD-10: I472, I4900 
All-cause mortalitya RPDB Vital status field 
Abbreviations: CIHI-DAD = Canadian Institute for Health Information Discharge 
Abstract Database, ICD-10 = International Classification of Diseases, Tenth Revision, 
NACRS = National Ambulatory Care Reporting System, RPDB = Registered Persons 
Database of Ontario 
aAll-cause mortality has a sensitivity of 97.8% and specificity of 100% (70). 
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Appendix E. Coding definitions for cause of death data in Ontario Registrar General 
Vital Statistics Database 
 
Cause of Death ICD-9 Codes 
Cardiovascular 
   Ischemic heart disease 4019, 4020, 4100, 4110, 4120, 4130, 4140, 4141, 4148, 
4149, 4230, 4292, 4298 
   Heart failure 3989, 4029, 4049, 4254, 4255, 4257-4259, 4280, 4281, 
4289, 7798 
   Cerebrovascular 430, 431, 435, 436, 438, 3448, 3623, 4320, 4321, 4329-
4333, 4338-4341, 4349, 4370, 4372-4376, 4378, 4379 
   Arrhythmia 4260, 4261, 4267, 4269-4276, 4278, 4279, 4299, 7850, 
7853, 9960, v450, v533 
   Valvular heart disease 393, 3940-3942, 3949-3952, 3959, 3960, 3970, 3979, 
3980, 3989, 4010, 4011, 4039, 4240-4243, 4249 
   Other 4151, 4400-4402, 4408-4415, 4419-4423, 4428-4431, 
4438-4442, 4448, 4449, 4470-4472, 4474-4476, 4478-
4481, 4489, 7982, 7989, 9960 
Infection 
   Abdominal 0020-0023, 0029-0032, 0038-0043, 0048, 0049, 0060-
0066, 0068-0072, 0078-0080, 0084-0086, 0088, 0093, 541-
543, 0700-0703, 0705, 0706, 0709, 5400, 5401, 5409, 
5740-5743, 5745, 5750-5756, 5758, 5759 
   Cardiac 4209, 4229 
   Kidney/genitourinary 0900-0907, 0909-0913, 0919, 0929, 0939, 0943, 0948-
0950, 0960, 0970, 0971, 0979, 5900, 5990 
   Neurological 064, 0360, 0362-0364, 0368, 0369, 0620-0625, 0628-0630, 
0632, 0638, 0639, 3200-3203, 3207-3210, 3218 
   Respiratory 0130, 0131, 0138-0140, 0159, 0169, 0170, 0172-0174, 
0176, 0178, 0180, 0188, 0189, 0330, 0331, 0338, 0339, 
483, 4660, 4661, 4787, 4800-4802, 4808-4810, 4820-4824, 
4828, 4829, 4847, 4848, 4850, 4860, 4870, 4871, 4878, 
5110, 5118-5120, 5140, 5172, 5178, 5180-5182, 5185, 
5188, 5190, 5191, 5193, 5194, 5198, 5199, 7991, 9973 
   Septicemia 0380-0384, 0388, 0389 
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   Other 0010, 0011, 0019, 0050-0052, 0054, 0058, 0059, 0101, 
0200-0202, 0205, 0208-0210, 0220-0223, 0228-0233, 
0238-0240, 0250, 0260, 0261, 0269-0272, 0278, 0279, 
0300-0303, 0308-0311, 0318-0321, 0323, 0328, 0329, 
0341, 0350, 0370, 0390-0393, 0398-0400, 0408, 0410-
0419, 0429, 0451, 0452, 0459, 0461-0463, 0468, 0469, 
0478-0480, 0490, 0491, 0498, 0499, 0509, 0519, 0520, 
0530-0532, 0537, 0539-0547, 0549-0552, 0557, 0559, 
0560, 0567, 0569, 0570, 0578, 0579, 0600, 0601, 0609, 
0610, 0650-0652, 0654, 0658-0663, 0668, 0669, 0710, 
0720-0723, 0727, 0729, 0730, 0740, 0741, 0743, 0750, 
0760, 0761, 0769, 0771-0774, 0778-0781, 0783, 0785-
0788, 0790, 0798-0800, 0810-0812, 0819-0822, 0823, 
0829-0832, 0838-0844, 0846, 0849, 0850, 0855, 0859-
0865, 0870, 0871, 0879, 0880, 0888, 0980, 0981, 0984-
0988, 0990-0992, 0998-1000, 1008, 1009, 1020-1033, 
1039, 1040, 1048, 1049, 1100-1105, 1108-1113, 1118-
1125, 1128, 1129, 1140, 1150, 1151, 1159-1162, 1170-
1172, 1174-1177, 1179, 1180, 1200-1203, 1208-1214, 
1218-1221, 1223-1236, 1238-1240, 1250-1253, 1255-
1257, 1259, 1261, 1268-1281, 1288-1290, 1300, 1310, 
1318-1323, 1329, 1330, 1338, 1340-1342, 1348, 1349, 
1362, 1363, 1368-1374, 1380, 1390, 1391, 1398, 3240, 
4298, 6829, 7713 
Cancer 
   Malignant 1400, 1401, 1403-1406, 1408-1414, 1416, 1418-1422, 
1428-1431, 1439-1441, 1448-1456, 1458-1464, 1466-
1473, 1478-1483, 1488-1491, 1498, 1500-1505, 1508-
1516, 1518-1523, 1528-1543, 1548, 1550-1552, 1560-
1562, 1568-1574, 1578-1580, 1588-1591, 1598-1605, 
1608-1613, 1618-1620, 1622-1625, 1628, 1629, 1639-
1643, 1648-1650, 1658, 1659, 1700-1710, 1712-1746, 
1748, 1749, 1790, 1800, 1801, 1808-1810, 1820, 1821, 
1828, 1830, 1832-1835, 1838-1844, 1848-1850, 1860, 
1869, 1871-1894, 1898-1906, 1908-1923, 1928-1930, 
1940, 1941, 1943-1946, 1948-1955, 1958, 1960-1963, 
1965, 1966, 1968-1978, 1980-1988, 1990, 1991, 2000-
2002, 2008, 2011, 2014-2017, 2019-2026, 2028-2031, 
2038, 2040, 2041, 2048-2051, 2053, 2058-2060, 2068-
2070, 2072, 2078, 2080, 2081, 2088, 2089, 2387, 2733, 
2849, 2850, 2898 
   Non-malignant 2100-2140, 2150, 2152-2157, 2159-2167, 2169, 2170, 
2180, 2190, 2191, 2198-2200, 2210-2212, 2218-2224, 
2228-2233, 2238-2246, 2249-2254, 2258-2260, 2270, 
2271, 2273-2276, 2278-2281, 2290, 2298, 2299 
70 
 
 
 
Other 
   Chronic lung disease 1173, 4900, 4910-4912, 4918-4920, 4930, 4931, 4939, 
4940, 4950-4960, 5000, 5010, 5020, 5030, 5040, 5050, 
5163 
   Diabetes 2500-2502, 2504-2507, 2510 
   Neurological and  
   dementias 
2900, 2901, 2904, 2908, 2909, 2940, 2941, 3030, 3078, 
3220, 3222, 3229, 3234, 3235, 3238-3241, 3249, 3250, 
3260, 3308, 3310-3314, 3317-3321, 3330-3342, 3344, 
3348-3352, 3360-3363, 3368-3371, 3379, 3400, 3410, 
3411, 3418-3421, 3429, 3430, 3432, 3434, 3438-3446, 
3448-3455, 3457-3462, 3468-3470, 3480-3485, 3488-
3490, 3492, 3498, 3499, 3501, 3502, 3508-3511, 3518-
3520, 3522-3526, 3529-3536, 3538-3545, 3548-3559, 
3561, 3563, 3564, 3568-3582, 3588-3596, 3598, 3599, 
3886, 7428, 7805, 7807, 7840, 7860, 9958, 9970 
   Digestive 2111, 2113, 5200-5236, 5238-5246, 5248-5253, 5258-
5265, 5268-5280, 5282-5286, 5288-5296, 5298-5317, 
5319-5327, 5329-5337, 5339-5347, 5349-5351, 5353-
5356, 5361, 5368, 5370, 5371, 5373, 5374, 5376, 5378, 
5379, 5500, 5501, 5509-5513, 5518-5523, 5528-5533, 
5538, 5539, 5550-5552, 5559, 5560, 5570, 5571, 5579, 
5580, 5600-5603, 5608, 5620, 5621, 5640-5643, 5645-
5651, 5660, 5670, 5672, 5678-5680, 5688-5696, 5698-
5700, 5710-5716, 5718-5721, 5723, 5724, 5728, 5730, 
5732-5734, 5738, 5739, 5759-5765, 5768-5772, 5778-
5781, 5789-5794, 5798, 5799, 9974 
   Suicide and accidents E000-E030, E800-E807, E810-E838, E840-E858, E860-
E876, E878-E888, E890-E999 
   Other Every other code 
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Appendix F. Standard daily drug doses for the treatment of respiratory tract infections 
 
Drug Standard daily doses (mg)a 
Macrolide antibiotics   
  Azithromycin 250 to 500 
  Clarithromycin 500 to 1,000 
  Erythromycin 500 to 2,000 
Non-macrolide antibiotics   
  Amoxicillin 750 to 1,750 
  Cefuroxime 500 to 1,000 
  Levofloxacin 500 to 750 
aPrescriptions for any daily drug doses that are not standard for the treatment of 
respiratory tract infections were excluded from our two groups to ensure generalizability 
to usual prescribing. 
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Appendix G. Variables included in the propensity score 
 
Variables Included in the Propensity Score 
Demographics 
Age 
Sex 
Neighbourhood income quintile 
Index date 
Rural residence 
Long-term care 
Local Health Integration Network 
Comorbidities 
Dementia 
Schizophrenia or related psychotic disorder 
Bipolar disorder 
Unipolar depression and/or anxiety disorder 
Haemorrhagic stroke 
Ischemic stroke 
Transient ischemic attack 
Chronic liver disease 
Chronic kidney disease 
Congestive heart failure 
Coronary artery disease 
Angina 
Peripheral vascular disease 
Parkinson's disease 
Chronic lung disease 
Atrial fibrillation/flutter 
Cancer 
Alcoholism 
Seizure 
Acute kidney injury 
Acute myocardial infarction 
Pacemaker 
Hyperkalemia 
Hypotension 
Prostatic hyperplasia 
Prostatitis 
Acute urinary retention 
Deep vein thrombosis/Pulmonary embolism 
Charlson comorbidity index 
Johns Hopkins Aggregated Diagnosis Groups 
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Medications 
Antiarrhythmic 
Antipsychotic 
Proton pump inhibitor 
Antiemetic 
Lithium 
Antilipemic 
Antihypertensive 
Potassium sparing diuretic 
Histamine H2-receptor antagonist 
Prokinetic 
QT-prolonging 
Antidiabetic 
Acetylsalicylic acid 
Anticoagulant (excludes warfarin) 
Antiplatelet 
Tricyclic antidepressant 
Opioid 
Antimalarian 
Antiviral 
Antineoplastic 
Benzodiazepine 
Non-steroidal anti-inflammatory drug (excludes acetylsalicylic 
acid) 
Anticonvulsant 
Angiotensin-converting enzyme inhibitor or angiotensin II 
receptor blocker 
Beta-adrenergic antagonist 
Calcium channel blocker 
Non-potassium sparing diuretic 
Statin 
Antiparkinson drug 
Digoxin 
Overactive bladder medication 
Warfarin 
Inhaler - acetylcholine 
Inhaler - corticosteroid 
Inhaler - beta-agonist 
Smoking cessation aid 
Health Care Use 
Number of any hospitalizations 
Number of any emergency room visits 
General practice/Family practice visit 
Nephrology visit 
Cardiology visit 
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Investigations (a 
surrogate marker of 
health care access) 
Carotid ultrasound 
Cardiac catheterization 
Coronary angiogram 
Echocardiography 
Electroencephalography 
Holter monitoring 
Cardiac stress test 
Coronary revascularization 
Electrocardiography 
Colorectal cancer screening 
Cervical cancer screening 
Prostate-specific antigen test 
Mammography 
Influenza vaccination 
Bone mineral density test 
Hearing test 
Cystoscopy 
Transurethral resection of the prostate 
Computed tomography of the head 
Computed tomography of other areas 
Chest x-ray 
Pulmonary function test 
At-home physician service 
Urinalysis 
Sputum 
Other 
Prescriber specialty 
Number of medications (polypharmacy) 
Baseline serum creatinine measurement 
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Appendix H. QT-prolonging drugs included in subgroup analysis 
 
Drug Name Drug Identification Numbers 
Amiodarone hydrochloride 00705934, 02036282, 02239835, 02240071, 02240604, 
02242472, 02243836, 02245781, 02246194, 02364336 
Amitriptyline 00016306 
Amitriptyline 
hydrochloride 
00016322, 00016330, 00016349, 00037400, 00037419, 
00037427, 00335053, 00335061, 00335088, 00377872, 
00377880, 00377899 
Amitriptyline 
hydrochloride & 
perphenazine 
00140651, 00176931, 00176966 
Amoxapine 00527084, 00527092, 00527106, 00527114, 02169886, 
02169894, 02169908 
Amprenavir 02243541, 02243542, 02243543 
Aripiprazole 02322374, 02322382, 02322390, 02322404, 02322412, 
02322455 
Atazanavir 02248610, 02248611 
Chloroquine 00021261 
Chloroquine diphosphate 00033642, 01912984, 02017539 
Chlorpromazine 00025151, 00025186, 01929968 
Chlorpromazine 
hydrochloride 
00025178, 00025453, 00025461, 00025488, 00025496, 
00025518, 00232157, 00232807, 00232823, 00232831, 
00580988, 01929909, 01929917, 01929925, 01929933, 
01929941, 01929976, 01929992 
Cisapride 00836311, 00836338, 00836354, 02054817 
Cisapride monohydrate 09852913 
Citalopram hydrobromide 02239607, 02239608, 02246056, 02246057, 02246594, 
02246595, 02248010, 02248011, 02248050, 02248051, 
02248170, 02248171, 02248944, 02251558, 02251566, 
02252112, 02252120, 02275562, 02275570, 02285622, 
02285630, 02293218, 02293226, 02301830, 02304686, 
02304694, 02306239, 02306247, 02313405, 02313413, 
02322781, 02322803, 02331950, 02331977, 02353660, 
02353679, 02355256, 02355272, 02355280, 02371898, 
02371901, 09852913 
Clomipramine 02040751, 02040778, 02040786, 02130165, 02130173 
Clomipramine 
hydrochloride 
00324019, 00330566, 00402591, 02139340, 02139359, 
02139367, 02230063, 02230064, 02230065, 02230256, 
02244816, 02244817, 02244818 
Darunavir 02284057, 02324016, 02324024, 02338432, 02393050 
Desipramine hydrochloride 00010448, 00353868, 00353876, 00425265, 00776157, 
01946242, 01946269, 01946277, 01948776, 01948784, 
01948792, 01948806, 02024896, 02024918, 02024926, 
02099128, 02099136, 02211947, 02211955, 02211963, 
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02216248, 02216256, 02216264, 02216272, 02223325, 
02223333, 02223368 
Dextropropoxyphene 
hydrochloride 
00151351 
Dextropropoxyphene 
napsylate 
00261432 
Disopyramide 00382876, 00439363, 01989553, 01989561, 02224801, 
02224828 
Disopyramide phosphate 00396370, 00396389, 00584231, 00619760, 01989545, 
02030799, 02030802, 02030810, 02224836 
Dolasetron mesylate 02231378, 02231379 
Domperidone 00642851, 00855820, 02157195 
Domperidone maleate 01912070, 02103613, 02230473, 02231477, 02236466, 
02268078, 02350440, 02369206, 02403870 
Doxepin hydrochloride 00024325, 00024333, 00024341, 00326925, 00400750, 
00584274, 00842745, 00842753, 00842761, 00842788, 
00842796, 00842818, 01913441, 01913468, 01913476, 
02049996, 02050005, 02050013, 02050021, 02050048, 
02050056, 02140071, 02140098, 02140101, 02140128, 
02144123, 02144131, 02144158 
Escitalopram oxalate 02263238, 02263254 
Flecainide acetate 00628220, 00817147, 01966197, 01966200, 02275538, 
02275546 
Fosamprenavir calcium 02261545 
Hydroxychloroquine 02246691, 02252600 
Hydroxychloroquine 
sulfate 
00033669, 01928287, 02017709 
Imipramine 00377902, 00377929 
Imipramine hydrochloride 00010464, 00010472, 00010480, 00021504, 00021512, 
00021520, 00312797, 00326852, 00360201, 00377910 
Indinavir sulfate 02229161, 02229196 
Lopinavir & ritonavir 02243643, 02243644, 02285533, 02312301 
Maprotiline hydrochloride 00360481, 00360503, 00360511, 00641855, 02158604, 
02158612, 02158620, 02158639 
Mesoridazine besylate 00027448, 00027456, 00027464, 00027448, 00027456, 
00027464 
Methadone 09850619, 09851771, 09852891 
Methadone hydrochloride 09857217, 09857218, 09857219, 09857220, 09857221, 
09857223 
Mexiletine 00599956, 00599964, 02231690, 02231692 
Mexiletine hydrochloride 02230359, 02230360 
Moxifloxacin 
hydrochloride 
02242965 
Nelfinavir mesylate 02238617, 02238618, 02248761 
Ondansetron 02239372, 02239373 
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Ondansetron hydrochloride 02229639, 02258188, 02258196, 02264056, 02264064, 
02274310, 02274329, 02278529, 02278537, 02288184, 
02288192, 02291967, 02296349, 02296357, 02297868, 
02297876, 02305259, 02305267, 02306212, 02306220, 
02312247, 02312255, 02313685, 02313693, 02371731, 
02371758, 02376091, 02376105, 02389983, 02389991 
Ondansetron hydrochloride 
dihydrate 
02344440, 02344459 
Paroxetine 02262754, 02262762 
Paroxetine hydrochloride 01940473, 01940481, 02027887, 02240907, 02240908, 
02240909, 02247751, 02247752, 02247811, 02247812, 
02248012, 02248013, 02248014, 02248451, 02248452, 
02248557, 02248558, 02254751, 02254778, 02269430, 
02269449, 02282860, 02368870, 02368889, 02383284, 
02383292 
Pimozide 00313815, 00313823, 00573817, 02245432, 02245433 
Probucol 00749044 
Procainamide 
hydrochloride 
00029076, 00296031, 00353523, 00638676, 00638684, 
00638692, 00639885, 00713325, 00713333, 00713341 
Propafenone 02343053, 02343061 
Propafenone hydrochloride 00603708, 00603716, 02243324, 02243325, 02243727, 
02243728, 02245372, 02245373, 02294559, 02294575 
Propoxyphene 
hydrochloride 
00010081 
Protriptyline hydrochloride 00322741 
Quetiapine fumarate 02236951, 02236952, 02236953, 02240862, 02244107, 
02284235, 02284243, 02284278, 02284286, 02296551, 
02296578, 02296594, 02296608, 02299062, 02300184, 
02300192, 02300206, 02300214, 02307804, 02307812, 
02307839, 02307847, 02311704, 02311712, 02311747, 
02311755, 02313901, 02313928, 02313936, 02313944, 
02313995, 02314002, 02314010, 02314029, 02316080, 
02316099, 02316110, 02316129, 02317893, 02317907, 
02317931, 02321513, 02330415, 02330423, 02330458, 
02330466, 02353164, 02353199, 02387794, 02387808, 
02387824, 02390205, 02390213, 02390248, 02390256, 
02395444, 02395452, 02395460, 02395479, 02395487, 
02397102 
Quinidine gluconate 00311731, 00704644 
Quinidine 
polygalacturonate 
00026131 
Quinidine sulfate 00004782, 00021733, 00023868, 00026883, 00094412, 
00249580, 00346837, 00441740, 01913883 
Ritonavir 02229137, 02229145, 02241480, 02357593 
Saquinavir mesylate 02216965, 02239083, 02279320 
Sotalol 02229778, 02229779, 02229780, 02234013, 02257858 
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Sotalol hydrochloride 00483923, 00897272, 02084228, 02084236, 02163772, 
02167794, 02170841, 02210428, 02230650, 02231181, 
02231182, 02238326, 02238327, 02238415, 02270625, 
02270633, 02368625 
Thioridazine hydrochloride 00027359, 00027375, 00027529, 00027537, 00027545, 
00027553, 00037478, 00037486, 00037494, 00037508, 
00238775, 00360198, 00360228, 00360236, 00360244, 
00456063, 00456071, 00456098, 00456101, 00575119, 
00575127, 00575135, 00575143, 00775320, 02229553 
Trimipramine 01940449, 01940457 
Trimipramine maleate 00025828, 00025836, 00025844, 00025852, 00442437, 
00740799, 00740802, 00740810, 00740829, 00761605, 
00761613, 00761621, 00761648, 00761656, 01926284, 
01926322, 01926330, 01926349, 01926357, 01940430, 
02020602, 02020610, 02020629, 02070987 
Ziprasidone hydrochloride 02298597, 02298600, 02298619, 02298627 
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Appendix I. 30-day cause of death in matched cohort of patients prescribed macrolide 
antibiotics (azithromycin, clarithromycin or erythromycin) compared to referent non-
macrolide antibiotics (amoxicillin, cefuroxime or levofloxacin)a 
 
Cause of deathb Macrolide (n = 503,612) 
Non-Macrolide 
(n = 503,612) 
Standardized  
Differencec 
Cardiovasculard 638 (0.13) 755 (0.15) 1% 
Infectione 96 (0.02) 100 (0.02) 0% 
Cancerf 569 (0.11) 785 (0.16) 1% 
Otherg 429 (0.09) 551 (0.11) 1% 
aData are presented as the number (percentage) of patients. 
bCause of death was not available for 1,412 (0.3%) macrolide antibiotic users and 1,642 
(0.3%) non-macrolide antibiotic users in the matched cohort. 
cStandardized differences are less sensitive to sample size than traditional hypothesis 
tests. They provide a measure of the difference between groups divided by the pooled 
standard deviation; a value greater than 10% (0.1) is interpreted as a meaningful 
difference between the groups (71).  
dCardiovascular included death by ischemic heart disease, heart failure, cerebrovascular, 
arrhythmia and valvular heart disease. 
eInfection type included abdominal, cardiac, kidney/genitourinary, neurological, 
respiratory and septicemia. 
fBoth malignant and non-malignant cancers were considered. 
gOther causes of death included chronic lung disease, diabetes, neurological and 
dementias, digestive, suicide and accidents. 
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Appendix J. 14-day risk for hospital encounter with ventricular arrhythmia and all-cause 
mortality in matched cohort of patients prescribed macrolide antibiotics compared to 
referent non-macrolide antibiotics 
 
Outcome 
Events, n (%) 
Relative Risk 
(95% CI) P value Macrolide 
(n = 503,612) 
Non-Macrolide 
(n = 503,612) 
Ventricular 
arrhythmiaa 71 (0.01) 72 (0.01) 0.99 (0.71-1.37) 0.93 
All-cause 
mortality 1,687 (0.34) 2,061 (0.41) 0.82 (0.77-0.87) < 0.0001 
Abbreviations: CI = confidence interval 
aBased on hospital presentation (emergency room or hospitalization) assessed by 
hospital diagnosis codes. This method of assessment underestimated the true number of 
events as ventricular arrhythmias frequently go undetected in routine healthcare 
(because they often occur outside hospital settings, in unmonitored patients in hospital 
or in a setting of multi-organ medical illness where recorded codes describe other 
illnesses besides the ventricular arrhythmia). 
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